## Page 1

pharmaceuticals
Review
Pharmacology of Herbal Sexual Enhancers: A Review
ff
of Psychiatric and Neurological Adverse E ects
PietroBrunetti1,AlfredoFabrizioLoFaro1,AnastasioTini2,FrancescoPaoloBusardò1,*
andJeremyCarlier1,2
1 UnitofForensicToxicology,SectionofLegalMedicine,DepartmentofExcellenceofBiomedicalSciences
andPublicHealth,MarchePolytechnicUniversity,60126Ancona,Italy;pietrobrunetti40@gmail.com(P.B.);
fabriziolofaro09@gmail.com(A.F.L.F.);jerem.carlier@gmail.com(J.C.)
2 UnitofForensicToxicology,SectionofLegalMedicine,DepartmentofAnatomical,Histological,Forensic,
andOrthopedicSciences,SapienzaUniversityofRome,00198Rome,Italy;anastasio.tini78@gmail.com
* Correspondence: fra.busardo@libero.it;Tel.:+39-071-5964727
(cid:1)(cid:2)(cid:3)(cid:1)(cid:4)(cid:5)(cid:6)(cid:7)(cid:8)(cid:1)
(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)
Received: 9September2020;Accepted: 12October2020;Published: 14October2020
Abstract: Sexualenhancersincreasesexualpotency,sexualpleasure,orlibido. Substancesincreasing
libidoaltertheconcentrationsofspecificneurotransmittersorsexhormonesinthecentralnervous
system. Interestingly,thesamepathwaysareinvolvedinthemechanismsunderlyingmanypsychiatric
andneurologicaldisorders,andadversereactionsassociatedwiththeuseofaphrodisiacsarestrongly
expected. However, sexual enhancers of plant origin have gained popularity over recent years,
as natural substances are often regarded as a safer alternative to modern medications and are
easilyacquiredwithoutprescription. Wereviewedthepsychiatricandneurologicaladverseeffects
associated with the consumption of herbal aphrodisiacs Areca catechu L., Argemone Mexicana L.,
Citrus aurantium L., Eurycoma longifolia Jack., Lepidium meyenii Walp., Mitragyna speciosa Korth.,
PanaxginsengC.A.Mey, PanaxquinquefoliusL., Pausinystaliajohimbe(K.Schum.) PierreexBeille,
Piper methysticum G. Forst., Ptychopetalum olacoides Benth., Sceletium tortuosum (L.) N. E. Brown,
TurneradiffusaWilld. ex. Schult.,VoacangaafricanaStapfexScott-Elliot,andWithaniasomnifera(L.)
Dunal. AliteraturesearchwasconductedonthePubMed,Scopus,andWebofSciencedatabases
withtheaimofidentifyingalltherelevantarticlespublishedontheissueuptoJune2020. Mostof
the selected sexual enhancers appeared to be safe at therapeutic doses, although mild to severe
adverseeffectsmayoccurincasesofoverdosingorself-medicationwithunstandardizedproducts.
Druginteractionsaremoreconcerning,consideringthatherbalaphrodisiacsarelikelyusedtogether
withotherplantextractsand/orpharmaceuticals. However,fewdataareavailableonthesideeffects
ofseveralplantsincludedinthisreview,andmoreclinicalstudieswithcontrolledadministrations
shouldbeconductedtoaddressthisissue.
Keywords: aphrodisiac;sexualenhancer;plant;pharmacology;toxicology;psychiatry;neurology;
adverseeffect
1. Introduction
Sexual drive is influenced by biological, psychological, and social factors, but it can also
be affected by medications and medical conditions. Many prescription drugs and narcotics
(e.g., antidepressants, anxiolytics, antihistamines, antihypertensives, adrenergic receptor blockers,
antipsychotics,andopioids)cannegativelyimpactsexualdesire,inhibiterection,ejaculation,ororgasm,
andsoon. Contrariwise,manyaphrodisiacsubstancescanimprovesexualperformance. Inparticular,
substancesofnaturaloriginhavebeenusedworldwideformillenniaintraditionalmedicinestoboost
sexualdesire,sexualpleasure,orsexualbehavior[1],andtheuseofpsychoactiveand/orstimulant
Pharmaceuticals2020,13,309;doi:10.3390/ph13100309 www.mdpi.com/journal/pharmaceuticals

## Page 2

Pharmaceuticals2020,13,309 2of51
drugs during intercourse, i.e., chemsex, is on the rise [2]. Nowadays, sexual performance anxiety,
whichcontributestopsychogenicerectiledysfunction,isestimatedtoaffect9to25%ofmeninthe
UnitedStates,andphytotherapyisoftenemployedasatreatment[3]. In2007,approximately56%
ofinfertilecoupleshadsoughtmedicalcareworldwide[4]andmanyofthesecoupleshadoptedfor
supportivecomplementaryandalternativemedicinestotreatinfertility. In2010,intheUnitedStates,
approximately29%of428infertilecoupleshadutilizedanalternativetreatmentafter18monthsof
observation,59%ofwhichhadtakenherbaltherapy[5]. Naturalsubstancesaremistakenlybelievedto
beasaferalternativetomodernmedicationswithnosideeffects. Theyarealsoreadilyaccessibleonthe
Internetandspecializedmarketswithoutaprescription. Consequently,theuseofherbalsupplements
toenhancesexualdrivehasbecomeincreasinglypopular,andmorethan300,000intoxicationswere
reportedtopoisoncontrolcentersoverthelast20years[6,7].
AccordingtoSandroni,aphrodisiacscanbeclassifiedintothreecategoriesaccordingtowhether
theyincreasepotency(i.e.,effectivenessoferectioninmales),sexualpleasure,orlibido(i.e.,sexual
desire)[8]. Potency-enhancingsubstancestypicallyinducevasodilation,oftenthroughthenitricoxide
(NO)pathway,inducinghypotensionandpotentiallyharmfulcardiovasculareffects(e.g.,sildenafil
and L-arginine). Sexual pleasure-enhancing substances cause tumescence and lubrication of the
genitalmucosa,thereforeincreasingsensation(e.g.,cantharidin). Libido-enhancingsubstancesalter
the concentrations of specific neurotransmitters (e.g., dopaminergic and serotoninergic pathways)
orsexhormones(e.g.,pituitaryhormonesandtestosterone)inthecentralnervoussystem(CNS)[8].
Forexample,methamphetamineisasyntheticillicitpsychomotorstimulantaffectingthemesolimbic
dopaminepathway,whichplaysanessentialroleinmotivationandtherewardsystem. Asubstantial
body of evidence shows that acute methamphetamine use is associated with enhanced positive
sexualexperiencesandlibido, withagreaterlikelihoodofengaginginhigh-risksexualbehaviors.
Sexualbehavior,however,maybeimpairedduetochronicmethamphetamineexposure[9].
The modulation of neurotransmission is also involved in the mechanisms underlying many
psychiatricandneurologicaldisorders. Forinstance,althoughnotfullyunderstood,thedysregulation
ofmonoaminergicsystems,especiallythedecreaseinserotoninergic,dopaminergic,andadrenergic
neurotransmissions,seemstobetheprimarycauseofdepression[10]. Contrariwise,maniaisbelieved
to be the consequence of an excess of the same monoamines in specific regions of the brain [11].
Schizophrenia,however,mainlyinvolvesdopaminergicandglutamatergicneurotransmissions[12].
Inneurology,adeficitofdopamineduetothedeathofcellsinthesubstantianigraistheprimarycause
ofParkinson’sdisease,whileAlzheimer’sdiseaseisduetothedegenerationofthehippocampusand
theraphenuclei,affectingthecholinergicpathway[13]. Thedrugsapprovedtotreatpsychiatricand
neurologicalconditionsmainlytargettheseneurotransmissionpathways.
Consideringthemechanismofactionofsexualenhancers,psychiatricandneurologicaladverse
effectsassociatedwiththeirconsumptionarestronglyexpected. In2014,Corazzaetal. reviewedthe
psychoactiveeffectsoffourpopularsexualenhancers[6]. InMarch2020,Srivatsavetal. reviewed
theefficacyandthesafetyprofileofseveralcommonaphrodisiacsusedinthetreatmentoferectile
dysfunction,butthestudywasnotexhaustiveandpsychiatricandneurologicaladverseeffectswerenot
addressed[14]. Inthisreview,weaimedtosummarizeandinterpretthefindingsofcasesandpreclinical
andclinicalstudiesreportingpsychiatricandneurologicaladverseeffectsassociatedwiththeuseof
aphrodisiacsofplantorigin. Apreliminaryscreeningoftheliteratureallowedfortheidentificationof
severalplantswithpotentialpsychiatricorneurologicalcomplications,whichwerethereforeincluded
inthisreview: ArecacatechuL.,ArgemoneMexicanaL.,CitrusaurantiumL.,EurycomalongifoliaJack.,
Lepidium meyenii Walp., Mitragyna speciosa Korth., Panax ginseng C. A. Mey, Panax quinquefolius L.,
Pausinystaliajohimbe(K.Schum.) PierreexBeille,PipermethysticumG.Forst.,Ptychopetalumolacoides
Benth.,Sceletiumtortuosum(L.)N.E.Brown,TurneradiffusaWilld. ex. Schult.,VoacangaafricanaStapfex
Scott-Elliot,andWithaniasomnifera(L.)Dunal.

## Page 3

Pharmaceuticals2020,13,309 3of51
Pharmaceuticals 2020, 13, x FOR PEER REVIEW 3 of 52
2. Results
OOff 55225555p opteontetniatlilayllrye lervealenvtarnetp orretps,o4r7ts5,8 4w7e5r8e ewxcelrued eedxcbluecdaeuds ebtheceayudsied tnhoetyd edsicdri bneopt sydcehsicartirbice
oprsyncehuiarotrliocg oicra nleaudrvoelorgseicaelff aedctvserosre beeffceacutss eort hbeeycawuseer ethneoyt wwerriett ennoti nwrEitntegnli sihn, EFnrgelnischh,, ForrenItcahl,i aonr
lIatanlgiauna glaen.gNuoagreel.e Nvaon rterleepvoarntts rweperoertfso wunedref oforuAn.dM foexri cAa.n Ma,eEx.icloanngai, fEol.i alo,nLg.imfoeliyae,n Lii., mT.eydeiffnuiis, aT,.V d.iafffuriscaa,n Va.,
aanfrdicWan.as,o amnndi fWera. ,swomhnicihferwa,e wrehthicehr ewfoerree etxhcelruedfoerdef eroxmcluthdeedre fsruolmts. tAhet oretasuloltfs1. 3A7 troetcaolr odfs 1w3e7r reeicnocrldusd wedeirne
tihneclfiundaeldr einv itehwe ;fisnpaelc rieesv-ibeyw-s; pspeceiceisess-ebayrc-shpreecsiuelst sseaarrecdhe rteasiuleldtsi anrae dfleotwaildeida ginra am flionwF digiuagrera1m. A ing Feingeurrael
d1.e sAcr ipgteinoenraolf deaescchrispptieocnie soifn celaucdhi nsgpetchieeisr tinracdluitdioinnga ltahnedir mtroaddeitrinonuasl esa,nadc tmivoedienrgnr eudsieens,t sawctiivthe
tihnegirremdieecnhtsa nwisitmh tohfeaicr tmioencahnadnipsmha ormf aacctoioknin aentidc sp,hanardmgaecnoekrianlettoicxsi,c iatny,di sgpenroevraidl etodxiincittyh,e ids ipscrouvssidioend.
Pins ythche idaitsrcicusasniodn.n Pesuyrcohloiagtircica lanadd vneerusreoleovgeincatsl ardepveorrstee deviennttsh ereplioterrtaedtu irne tharee lidteirsaptluaryee adrei ndiTspablalyee1d;
sintu Tdaybcleo n1d; sittiuodnys aconnddcioti-oenxps oasnudr ecso-aerxepaolssourdeest aarilee dal.so detailed.
Identification Eligibility: Included:
and screening: Records selected Records
Records screened for full-text review included
(title and abstract)
I H H
A. catechu n = 252 n = 70 n = 22
I H H
C. aurantium n = 45 n = 25 n=4
H H
[
M. speciosa n = 148 n = 78 n = 34
H H
P. ginseng and [
n = 743 n = 108 n = 18
quinquefolius
H H
[
P. johimbe n = 3682 n = 105 n =41
H H
P. methysticum ( n = 296 n = 83 n = 15
H H
P. olacoides n = 10 n=9 n=2
H H
S. tortuosum n = 79 n = 19 n=l
F F i i g g u u r r e e 1 1 . . SSppeecciieess--bbyy--ssppeecciieess flflooww ddiiaaggrraamm ooff lliitteerraattuurree sseeaarrcchh..

## Page 4

Pharmaceuticals2020,13,309 4of51
Table1. Reportsofpsychiatricandneurologicaladverseeventsassociatedwithherbalaphrodisiacs.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Casereportsofacuteintoxicationswith
Fluphenazinedecanoate, ArecacatechuL.intwoschizophrenicmen Rigidity,bradykinesia,akathisia,
[15]
procyclidine,flupentixol aged51and45;bothpatientsconsumeda andtremors
highquantityofbetelnutsfor2weeks
Moodswings,anxiety,irritability,
Surveystudyon11participantsaged27–70
Tobacco,alcohol, (average=52),9malesand2females; reducedconcentration,reduced [16]
cannabis,amphetamine chewed6nuts/week(range=4–6days) energy,sleepdisturbance,craving,
tolerance,anddependence
Longitudinalpilotstudyon
Tobacco,salbutamol,tea,coffee,arsenic (± 1 S 0 D 0 ) p a a g r e ti o ci f p 4 a 0 n .0 ts ( , ± 2 9 6 ) u y s e e a r r s s w ,1 i 1 th m a a m le e s a a n nd Enhancementofphysiologicaltremor [17]
15women
Cross-sectionalstudyon310pregnant
women,292users,meanageof26years
Tobacco,alcohol (range=25–27);took5–10nuts Addiction [18]
ArecacatechuL. duringpregnancy
Surveystudyon59participants,47males
Tobacco and12females,medianageof43.0years Cravinganddependence [19]
(range=12–70);1–50yearsofchewing
Cross-sectionalstudyon851participants,
aged16–35,314users,242tobacco+users,
Tobacco and295regularcigarettesmokers;<6–>10 Toleranceandwithdrawal [20]
yearsofchewing
IntercountryAsianBQConsortiumstudy
on2078participantswhotookanyA. Tolerance,withdrawal,craving,
Tobacco,alcohol catechuproducts/dayforaminimumof anddependencesyndrome [21]
6months
Surveystudyon41participantswitha
mean(±SD)ageof40.34(±9.23)years, Relaxation,stimulation,addiction,
Tobacco,alcohol [22]
27malesand14females;took5tomore andwithdrawalsymptoms
than31BQ/day

## Page 5

Pharmaceuticals2020,13,309 5of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Observationalstudyon152participants
Benzodiazepines,carbamazepine,
withepilepsy,50userswithameanageof
levetiracetam,phenobarbital,
28.4(95%CI:25.3,31.6)years,23malesand Drowsiness [23]
phenytoin,sodiumvalproate,other 27women;chewed1–20nuts/dayformore
medications(notspecified)
than5years
Dependence,tolerance,withdrawal,
attentionalbias,impairedwork,
Epidemiologicalstudiesofdependenceon impairedtimeperception,
Tobaccoandalcohol- 4031participants andincreasedarousal [24]
Casereportoftwowomen Poorconcentration,lethargy,
despondency,andepisodesof
paranoia(1individual)
Surveystudyon200participants,
Tobacco 171malesand29femalesaged22–45years; Addiction [25]
chewed4.3nuts/day
Nicotine,arecaidine(1.46µg/mLin w C i r t o h ss a - m se e c a ti n on (± al SD su ) r a v g e e y o o f n 40 1 . 1 0 3 ( p ± a 1 r 2 t . i 6 c ) ip y a e n ar t s s , CravingforBQ,addiction, [26]
urine),N-methylnipecotate,cotinine depression,anddrowsiness
104malesand9females
CholinergicREMinductionteston
34participants: 14bipolarpatientswitha
mean(±SD)ageof30(±6.1)years,6males
and8females;15HCvolunteerswitha
Methscopolamine
mean(±SD)ageof26.8(±4.4)years, Sho
p
r
r
t
i
e
m
r
a
R
r
E
y
M
aff
l
e
a
c
te
ti
n
v
c
e
y
d
i
i
n
so
p
r
a
d
t
e
ie
r
n
s
t
(
s
1
w
st
ith
[27]
8malesand7females;and5subjectswith
Arecoline
apersonalorfamilyhistoryofaffective and3rd)
disorders,agerangedbetween23and
35years,2malesand3females;
administeredwith0.5mgofarecoline
Pilotdose–responsestudyon Nausea,vomiting,increasedanger,
24participants,8bipolarsubjectsand16 confusion,depression,fatigueand
Glycopyrrolate [28]
HCmonozygotictwins;administeredwith tension,decreasedelation,
1or12mgofarecolineIPand4or12mgSC friendliness,andvigor

## Page 6

Pharmaceuticals2020,13,309 6of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
ArecolineREMinductionteston
97participants: 20MDDpatientswitha
meanageof46.6years(range22–83),
8malesand12females;19MDD+ANX
patientswithameanageof40.0years
(range21–47),7malesand12females;18
RapidREMinductioninMDDand
Glycopyrrolate ANXpatientswithameanageof32.2years MDD+ANXpatientscomparedto [29]
(range22–51),8malesand10females;
14ANX+MDDpatientswithameanageof healthycontrols
32.8years(range23–38),4malesand
10females;and26healthycontrolswitha
meanageof36.4years(range20–87),
11malesand15females;administeredwith
0.5mgofarecoline
Animalstudyon265SpragueDawleyrats;
Methylatropine administeredwith2mg/kgofarecoline Decreasedlocomotoryactivity [30]
Cognitiveandbehavioralstudyon
12participantswithAD,meanageof Decreasedknowledgememory,
Glycopyrrolate 65.5years(range54–79),4malesand psychomotorretardation,dysphoria, [31]
8females;administeredwith0.5and anddifficultywithverbalexpression
12mg/hofarecolinefor1to6h
ArecolineREMinductionteston
30participants: 10withatypicaldepression
withamean(±SD)ageof33.5(±7.8)years, RapidREMinductioninatypical
depressiveswithoutahistoryofpanic
Glycopyrrolate 4malesand6females,and20HCwitha [32]
mean(±SD)ageof34.5(±13.8)years, attacksoranxietydisorders
comparedtoHC
10malesand10females;administeredwith
0.5mgofarecoline

## Page 7

Pharmaceuticals2020,13,309 7of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
CatecholamineandACTHresponsestoan
arecolinestudyon31participants: 15MSA
patientswithamean(±SD)ageof
57.9(±1.8)years,8malesand7females; Mildvertigo,nystagmus,nausea,
Glycopyrrolate 6PAFpatientswithamean(±SD)ageof exacerbationoftremor,andalteration [33]
52.3(±1.8)years,2malesand4females; inmood
and10HCwithamean(±SD)ageof58.5
(±4)years,7malesand3females;
administeredwith0.3mgofarecoline
Randomized,double-blind,
placebo-controlledstudyon111participants:
40placebo-receivingsubjects,including
20depressedpatientswithamean(±SD)age
of39(±12)yearsand20HCwithamean
(±SD)ageof28(±6)years;38subjects
receiving0.5mgofarecoline,including21 ShorterREMlatencyin
Glycopyrrolate depressedpatientswithamean(±SD)ageof depressedpatients [34]
38(±9)yearsand17HCwithamean(±SD)
ageof28(±6)years;and33subjectsreceiving
1.0mgofarecoline,including18depressed
patientswithamean(±SD)ageof42(±11)
yearsand15HCwithamean(±SD)ageof
34.5(±13.8)years
CholinergicREMinductionteston
48participants: 33MDDchildrenwitha
mean(±SD)ageof10.5(±1.5)years,26males
ShorterREMlatencyin
- and7femalesand15HCchildrenwitha [35]
mean(±SD)ageof10.2(±1.6)years; depressedchildren
administeredwith0.5mgofarecolineover
60min
Animalstudyon63malealbino
Accelerateddecayofmemoryafter
- Wistar-derivedrats;administeredwith0.5, [36]
1.5,or3.5mg/kgofarecolineSCbeforetest chronicadministration

## Page 8

Pharmaceuticals2020,13,309 8of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyon96femaleSprague
- Dawleyrats;administeredwith40or80µg Decreasedlocomotoryactivity [37]
ofarecoline
Chlordiazepoxide,valproicacid, A a n d i m m i a n l i s s t t u er d e y d o w n i 1 th 76 0 a .5 d o u r lt 1 m .0 a m le g S / w kg is o s f m E i O ce; Increasedhypnoticeffectand
diazepam,sodium (90.4%ofd-limonene)and1.0mg/kgoffour enhancedsleepingtimeinduced [38]
pentobarbital,d-limonene differentfractionsofleavesextractorally bypentobarbital
Randomized,triple-blind,clinicalstudyon
156postmenopausalwomen:
52CA-receivingwomenwithamean(±SD)
ageof53.65(±3.55)years,
52lavender-receivingwomenwithamean
- (±SD)ageof54.21(±3.86)years, Headache,nausea,andhypnosis [39]
and52placebo-receivingwomenwitha
mean(±SD)ageof52.12(±3.49)years;
took2×500mg/dayofCApowderfor
6weeks
CitrusaurantiumL. Randomized,triple-blind,clinicalstudyon
156postmenopausalwomen:
52CA-receivingwomenwithamean(±SD)
ageof53.65(±3.55)years,
52lavender-receivingwomenwithamean
- (±SD)ageof54.21(±3.86)years, Headacheandnausea [40]
and52placebo-receivingwomenwitha
mean(±SD)ageof52.12(±3.49)years;
took2×500mg/dayofCApowderfor
6weeks
Randomized,double-blindclinicalstudy
on99femalestudentswithamean(±SD)
RosadamascenaMill. ageof22.33(±2.38)years,equallyparted Headache,nausea,andvomiting [41]
intotwointerventiongroupsandacontrol
group;inhaledEOofCAblossomat0.5%

## Page 9

Pharmaceuticals2020,13,309 9of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Dizziness,freshness,sprightliness,
Cross-sectionalstudyon433participants fatigue,shakinghands,headaches,
withamean(±SD)ageof45.7(±13.6)years, decreasedsexualdrive,
- 350malesand83females;149regularusers poorconcentration,distractedness, [42]
chewed12leaves/day,168occasionalusers difficultysleeping,irritability,
chewed4leaves/day,and116controls poorthinkingability,impairedmemory,
laziness,andsocialwithdrawal
Casereportofakratomintoxicationofa
43-year-oldmalewithchronicpainand Withdrawal,drowsiness,
Modafinil [43]
opioidwithdrawal;tookkratomteafour andgeneralizedtonic-clonicseizure
timesdailyfor3.5years
Casereportofakratomintoxicationofa
DaturastramoniumL.,cannabinoids,
64-year-oldmale,foundwith Seizuresandcoma [44]
tricyclicantidepressants,oxycodone 167±15ng/mLofmitragynineinurine
Mitragynaspeciosa
Cross-sectionalsurveyon136participants: Lossofweight,tiredness,
Korth. heroin,cannabis,amphetamine, 72short-termusersand64long-termusers, dose-dependentstimulation/sedation,
methamphetamine,mitragynine agerange=36–65years,135malesand intensecraving,withdrawal,chronic [45]
(67.5–75mg/day) 1female;took3×250mL/dayofkratom fatigue,insomnia,frequentsweating,
teafor3.5years andsuddennervepain
Wellbeing,euphoria,increased
Casereportofa44-year-oldkratom
productivity,industriousness,
addictedmalewithaprevioushistoryof
- relaxation,tolerance,withdrawal [46]
alcoholandcocainedependence;tookfrom
2×4g/dayto4×10g/dayfor3years symptomsofcravings,anxiety,
restlessness,anditch
Increasedalertness,dizziness,sedation,
hotsensation,hallucination,vomiting,
Cross-sectionalstudyon530MSusers, hostility,aggression,excessivetearing,
- 528malesand2females(agenotreported); inabilitytowork,achingofmuscles [47]
tookMStea1–10timesdailyfor4–5years andbones,jerkymovementoflimbs,
lossofappetite,weightloss,insomnia,
malaise,andrestlessness

## Page 10

Pharmaceuticals2020,13,309 10of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Seizure,nausea,alterationof
Amphetamine,haloperidol, Retrospectivestudyon52participantswith consciousness,contraction,confusion,
diphenhydramine, amedianageof30.5years(range: headache,dizziness,syncope,
[48]
codeine,depressants,unknown 2days–81years),84.6%malesand myalgia,insomnia,fatigue,lossof
chemicalsubstance 15.4%females appetite,agitation,tremor,ataxia,
dystonia,andneonatalwithdrawal
Wilddagga,wormwood,alprazolam, Agitation,nausea,vomiting,
14kratomexposuresreportedtotheTexas
syntheticcannabinoid,synthetic confusion,tremor,diaphoresis,
PoisonCenterNetworkof11malesand [49]
tryptamine,alcohol, drowsiness,hallucinations,mydriasis,
3femalesagedbetween18and48years
methamphetamine,risperidone andabdominalpain
Lossofappetite,cravingtoeat
kratom,withdrawal,compulsion,
impairedcontrol,preoccupation,
lossofweight,muscle/bone/back/joint
aches,cramps/numbness,anxiety,
Qualitativestudyon34maleparticipants:
22regularuserschewed10–80leaves/day depressedmood,dysphoria,
moodiness,annoyance,restlessness,
Alcohol for3–50years;6occasionaluserschewed [50]
1–20leaves/dayfor1–6years;3non-users; irr
h
it
y
a
p
b
e
il
r
i
/
t
h
y,
y
a
p
u
o
t
a
o
c
n
ti
o
v
m
it
i
y
c
,
n
ch
er
il
v
ls
o
,
u
s
s
n
s
e
y
e
s
z
t
e
e
,
m
and3ex-users cough,illness/catchcold,sleepy,
yawning,wateringeyes,runnynose,
stickymouth,disturbancesof
behaviorsandcognitivefunctions,
andfatigue
Sleepingdifficulty,decreased
appetite,nausea,vomiting,muscle
Cross-sectionalsurveyon293malekratom
spasm,sweating,fever,abdominal
userswithameanageof28.9years,
Mitragynine(291.9mg/day) 153medium-termusersand140long-term pain,headaches,hotflashes,hiccups, [51]
users;upto≥3×350mL/dayofkratom shakinessortremors,severemuscle
painandcramps,nervousness,
freshjuice
sadness,restlessness,anger,tension,
depressedmood,andcraving

## Page 11

Pharmaceuticals2020,13,309 11of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Warmth/tingling,
nausea/stomachache,alternating
Qualitativestudyon168kratomusers: chills/sweats,dizziness/unsteadiness,
- 109males,13females,and44others(sex [52]
vomiting,itching,numbnessin
notspecified) mouth/throat,visualalterations,
andsedation
660callsaboutkratomexposurereceived
byU.S.poisoncenters,themedianagewas
Alcohol,otherbotanicals, 28years(range=2months–69years, Agitation,irritability,drowsiness,
benzodiazepines,narcotics, [53]
dataavailablefor604subjects),472males andnausea
acetaminophen
and186females(dataavailablefor
658subjects)
Cross-sectionalstudyon526kratomusers Craving-fatiguesyndrome,
- withameanageof51.8years; moodsymptoms,insomnia, [54]
took3–17leaves/day andphysicalsickness
Casereportsoftwokratom-addicted
Dependence,tolerance,irritability,
subjects,a60-year-oldfemalewhotook
Tramadol,codeine,morphine increasedpain,anxiety,edginess, [55]
0.25ouncesofkratomevery4hforseveral
andlegshaking
months,anda57-year-oldmale
Retrospectivestudyon150male
participantswithamean(±SD)ageof34.4 Withdrawalsymptoms,anxiety,
- (±11.2)years;tookupto≥4×350mL/day anddepression [56]
ofkratomfreshjuice
Casereportofamaternal(a29-year-old
Anxietyandmaternaland
Morphine female)andneonatalkratomexposure; [57]
took3×18-20g/dayofkratompowder neonatalwithdrawal
Casereportofafemaleinfant’sNAS,
- hermothertook3–4kratomteas/day Excessivesucking,irritability, [58]
sleeplessness,andwithdrawal
duringherpregnancy

## Page 12

Pharmaceuticals2020,13,309 12of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Casereportofakratomoverdoseand
managementofwithdrawalofa
Unresponsiveness,seizures,
- 24-year-oldmanwithAspergersyndrome, [59]
andwithdrawal
depression,andlong-termsubstance
dependence;took600mg/dayofkratom
Casereportofakratomintoxicationofa
Lisdexamfetamine 19-year-oldmalewithADHD;tookseveral Seizures [60]
pills(2–8g)perdayforseveralmonths
Increaseddepression,anxiety,
Casereportofa52-year-old
suicidalthoughts,exacerbationof
kratom-addictedfemalewitha
Benzodiazepines chronicpainissues,dysphoria, [61]
long-standinghistoryofMDD;took1
nausea,muscleaches,sweating,
tablespoon4–6timesperdayfor9months
goosebumps,andinsomnia
Cross-sectionalstudyon95male
participants: 70kratomuserswithamean
- (±SD)ageof28.8(±5.3)whotook3glasses Visualmemoryandnew [62]
ofkratomtea/juicedaily,and25healthy learningimpairment
controlswithamean(±SD)ageof25(±7.6)
Auditory,visual,tactile,andolfactory
Cross-sectionalstudyon150malekratom
userswithamean(±SD)ageof34.4(±11.2) hallucinations,persecutory,reference,
- years;tookupto≥3glasses/dayformore controlandgrandiosedelusion [63]
thoughtbroadcasting,
than6years
andwithdrawal
Briefreporton2321kratomexposures,
Agitation,drowsiness,confusion,
ofwhich4casesofNASand2deathswere
seizure,withdrawal,hallucinations,
Alcohol,clonazepam,cocaine reported,and4deathsforwhichkratom [64]
respiratorydepression,coma,
waslistedasacauseorcontributingfactor
andcardiacorrespiratoryarrest
tothedeath
Casereportsofkratomintoxicationswith
Seizure,sedation,withdrawal
4maleswithameanageof43.5years
Alcohol,otherunknownsubstances (range=44–67);case2took4×10g/dayof symptoms, [65]
anddependencesyndrome
kratomover24h

## Page 13

Pharmaceuticals2020,13,309 13of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Cross-sectionalsurveyon163regular
kratommaleuserswithamean(±SD)age Weightloss,physicalpain,lossof
Opiate,methamphetamine,methadone of37.1(±10.9)years;took1–3glasses/day appetite,fatigue,cravingforopioid, [66]
insomnia,anddepression
ofkratomteaformorethan6years
Casereportsoftwokratomintoxications:
a27-year-oldmalewithbipolardisorder
andschizophreniawhotook5g/dayof Restlessness,generalizedbodyaches,
overwhelminganxiety,thoughtsof
- kratomfor3years,anda26-year-old [67]
suicide,hallucinations,
femalewithnohistoryofmentalhealth
disorderswhotook2–3pills/day(20–30g andwithdrawalsymptoms
ofkratom/day)for2years
Casereportofa22-year-oldmalewith
ADHDandkratomusedisorder; Tolerance,irritability,
Dextroamphetamine [68]
tookkratomteaevery2hdaily(30gat andwithdrawalsymptoms
maximumdosage)for2years
Casereportofa27-year-oldmalewitha
historyofANX,ADHD,benzodiazepine,
Diphenhydramine Tonic-clonicseizures [69]
andopioidusedisorders;tookupto
4×8mL/daybottlesofkratomfor1.5years
Onlineanonymouscross-sectionalsurvey
Alcohol,antidepressants, on2798kratomuserswithamean(±SD) Sickness,dizziness,alertness,anxiety,
benzodiazepines,cannabis,cocaine, ageof40.2(±11.8)years,1099malesand sleepiness, [70]
hallucinogens,opioids(prescribedor 1699females;tookupto3×1–6g/day andwithdrawalsymptoms
illicit),tobacco
ofkratom
Cross-sectionalquantitativestudyon356
participants,137kratomusersand219 Addiction,withdrawalsymptoms,
- non-usersagedbetween18and≥37years, andimpairedsocialfunctioning [71]
212malesand144females

## Page 14

Pharmaceuticals2020,13,309 14of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyon36malemicefromthe
ICRstrain: 18mitragynine-treatedmice
Scopolamine administeredwith5,10,or15mg/kgIPof Impairedworkingmemoryfunction [72]
andreductioninlocomotoryactivity
for28days;6scopolamine-treatedmice;
and12HC
7-hydroxymitragynine(0.15mg/Lin Fatalmitragynineintoxicationofa
blood,2.20mg/Linurine),zopiclone, m 3. i 4 d 7 d m le g -a /L ge o d f m m a it l r e a , g fo y u ni n n d e w in it b h lo 1 o .0 d 6 a a n n d d CNSdepression [73]
citalopram,lamotrigine
urine,respectively
AnimalstudyonmaleC57BL/6mice;
administeredwith1,5,10,or20mg/kgIP
Mitragynine 30minbeforeorimmediatelyafter Decreasedactivityintheδ,θ,andβ,
Morphine,methamphetamine, locomotorandconsolidationtests, butnotαbandinthehippocampus [74]
30mg/kgIPfor14daysforthewithdrawal andwithdrawal
inductionandfor28daysforthe
chronicstudy
Animalstudyon39maleFischer334rats;
Morphine,penicillinGprocaine, Increasedmorphine
administeredwith25,50,100,or150µgof
propofol,xylazine,ketamine, self-administrationafter [75]
mitragynineand2.5,5,10,or20µgof
naltrindole,naloxonazine 7-hydroxymitragyninetreatment
7-hydroxymitragynine
Animalstudyon60maleSpragueDawley
Impairedacquisitionofspatial
ratsandothersetofanimalsusedfor
learningandsignificantsynaptic
Morphine,urethane,xylocaine invivoelectrophysiologicalstudies; [76]
administeredwith1.0,5.0and10.0mg/kg depressioninthehippocampalregion
athighmitragyninedoses
ofmitragynineIP
Casereportofa47-year-oldfemalewith
Fluvoxamine,venlafaxine chronicdepression;took200mgofginseng Hypomania [77]
extractwithin24h
PanaxginsengC.A.
Mey Casereportofa26-year-oldmalewith
historyofsuicidalthoughts; Restless,insomnia,
- took250mg/dayofChineseginsengfor agitation,disorganization [78]
twoweeks

## Page 15

Pharmaceuticals2020,13,309 15of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Placebo-controlled,clinicalstudyon
20participantswith(mean(±SD)ageof
20.6(±4.2),10malesand10females;
Contraceptivepill,ginsenosides(4%) administeredwithplaceboand5×200,400, Decreasedspeedattention [79]
or600mgofginsengextractwitha7-day
wash-outbetweenadministrations
Placebo-controlled,clinicalstudyon
20participantswithamean(±SD)ageof
20.6(±4.2),10malesand10females;
GinkgobilobaL.,contraceptivepill. administeredwithplaceboand5×200,400, Decreasedspeedattention [80]
or600mgofginsengextractwitha7-day
wash-outbetweenadministrations
Casereportofginsengintoxicationofa Hyperactivity,insomnia,dysphoria,
Clomipramine MDD56-year-oldwoman;took300mg/day andverbalandphysical [81]
ofrootextractfor2weeks aggressiveness
Randomized,double-blind,
placebo-controlledclinicalstudyon
70post-menopausalfemales,
GinkgobilobaL.,vitaminsandminerals, 12ginseng-receivingsubjectswithamean
cold-liveroil,primroseoil, (±SD)ageof58.4(±1.0)yearsand Slightdepression(onecase) [82]
caffeine,alcohol 14placebo-receivingsubjectswithamean
(±SD)ageof57.4(±0.7)years;
administeredwith2×100mg/dayof
ginsengextractfor12weeks
Single-blind,placebo-controlledclinical
studyon14-anda17-year-oldADHD
Ginsenosides(27–30%) males;administeredwith2×250mg/day Mildsedation [83]
ofginsengextract

## Page 16

Pharmaceuticals2020,13,309 16of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Rg1,Rb1,Rg3,Re,Rc,Rb2,Rd,Rf,Rh1, Open-labelstudyon35MDDfemaleswitha
Rg2s,otherminorginsenosides, mean(±SD)ageof45.1(±9.5)years;
Headache,insomnia,
escitalopram,venlafaxine,paroxetine, administeredwith2gatday1ofredginseng [84]
duloxetine,citalopram,bupropion, extracttitratedat3g/dayfor4weeksand andhypersomnia
fluvoxamine,imipramine,trazodone maintainedforanother4weeks
Racingthoughts,anxiety,irritable
Cannabis 2
C
3
a
-
s
a
e
n
r
d
ep
a
o
7
r
9
ts
-y
o
e
n
ar
t
s
w
-o
o
ld
g
;
in
to
s
o
e
k
ng
gi
i
n
n
s
t
e
o
n
x
g
ica
(cid:27)
ti
1
o
5
n
a
s
n
o
d
f mood,labileaffect,disorganized
[85]
(cid:27)20g/day,respectively thoughtprocess,constantdistraction,
andauditoryhallucinations,
Open-labelstudyon30patientswith
cancer-relatedfatigueandunder
Chemotherapies,ginsenosides, chemotherapywithamedianageof58(range Pain,nausea,cognitivedisturbance,
malonylginsenosides =48–68)years,15malesand15females; andseizure [86]
administeredwith2×400mg/dayginseng
rootextractfor4weeks
Casereportofa42-year-oldfemalewithno
Multivitamins,herbalsupplements Psychosisandconfusion [87]
historyofpsychiatricissueorillicitdruguse
Casereportofaginsengintoxication(age,
- Mania [88]
sex,anddosenotspecified)
Randomized,double-blind,
placebo-controlledclinicalstudyon
74opioid-addictedparticipantsunder
Methadone methadonemaintenancetreatment,48males Sleepinessandagitation [89]
withameanageof40.64yearsand
26femaleswithameanageof39.0years;
administeredwith4×250mgofrootpowder
Casereportofa47-year-oldmalewithno Nervousness,aggressivebehaviors,
historyofpsychiatricdisorder;took600 irritability,increasedpsychomotor
- mg/dayginsengtoincreaseenergyand activity,decreasedsleep, [90]
sexualactivity andexcessivetalkativeness

## Page 17

Pharmaceuticals2020,13,309 17of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Open-labelstudyon40ADHDchildren
Eicosapentaenoicacid, withamean(±SD)ageof8(±1.45)years
Transitoryheadache(onecase) [91]
docosahexaenoicacid,Rg1,Rb1,Rg3 31malesand9females;administeredwith
3mg/dayginsengextractfor12weeks
Casereportofa42-year-oldfemalewith
Phenelzine,beepollen,other
chronicdepression,butnohistoryof Maniaandhallucinations [92]
naturalmedications
manicepisodes
Open-labelstudyon36ADHDchildren
withamean(±SD)ageof10.2(±3.7); Increasedimpulsiveness,
PanaxquinquefoliusL. GinkgobilobaL.,ritalin,efamol administeredwith2×200mg/dayof hyperactivityandaggressiveness, [93]
headache,andtiredness
ginsengextractfor4weeks
Multicenter,prospectivestudyon788with
Tamoxifen,otherestrogenic
breastcancer;103usedginsengafter Fatigue [94]
botanicalsupplements
cancerdiagnosis
Decreaseinspontaneouslocomotor
Animalstudyon101maleSpragueDawley activity,overreactiontoexternal
Corynanthine(5,20mg/kg) rats;administeredwith5or20mg/kgof stimuli,violenttremors,convulsions, [95]
yohimbineIP abnormalposture,anddecreasein
bodytemperature
Animalstudyon82reddeer(Cervus
Pausinystaliajohimbe(K. Xylazine, elaphusL.),administeredwith0.063,0.124, Rapidreactiontoexternalstimuli,
[96]
Schum.) Pierreex Doxapram,4-aminopyridine 0.125,0.128,0.189,0.20,0.21,0.23,0.24,0.25, anxiety,andnervousness
Beille(yohimbine)
or1.00mg/kgofyohimbineIV
Threecasereportsofmanicsymptoms
followingyohimbineadministrationof
threepsychiatricpatients: a41-year-old Tremors,nausea,generalized
Desipramine,bupropion,trazodone malewhotook10mgofyohimbineorally, restlessness,diaphoresis, [97]
and20-and43-year-oldfemaleswhotook andpalpitations
20mgofyohimbineintwosessionsand
onesession,respectively

## Page 18

Pharmaceuticals2020,13,309 18of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Randomized,double-blind,
placebo-controlledstudyon59participants:
39drug-freepatientswithagoraphobiaand
panicattacks—11maleswithamean(±SD)
ageof36.8(±8.2)yearsand29femaleswith Anxiety,nervousness,hotandcold
- amean(±SD)ageof38.8(±10.1)years; flashes,restlessness,tremors, [98]
and20HC—9maleswithamean(±SD) andpiloerection
ageof33.3(±7.3)yearsand11femaleswith
amean(±SD)ageof43.3(±7.4)years;
administeredwith4×5mgof
yohimbinecapsules
Weakness,generalizedparesthesia,
lossofcoordination,dissociative
Casereportofanacuteyohimbine
state,severeheadache,dizziness,
Acetylsalicylicacid intoxicationofa16-year-oldfemale; [99]
tremors,decreasedhearing,nausea,
took250mgofpowderedyohimbine
diaphoresis,
andintermittentpalpitations
Randomized,double-blind,
placebo-controlledstudyon88participants:
68agoraphobicsubjectswithpanicattacks
orpanicdisorder—19maleswithamean
(±SD)ageof38(±9)yearsand49females
- withamean(±SD)ageof40(±1)years; Increasedrateofpanic [100]
and20HC—9maleswithamean(±SD) attacks,anxiety
ageof34(±8)yearsand11femaleswitha
mean(±SD)ageof43(±7)years;
administeredwith4x5mgof
yohimbinecapsules
AnimalstudyonmalehoodedListerrats;
administeredwith2.5or5mg/kgof
Decreasedlocomotoryactivityand
- yohimbineIPforacuteexposureevaluation [101]
and2.5or5mg/kgdailyfor5daysfor increasedanxiety
chronicexposureevaluation

## Page 19

Pharmaceuticals2020,13,309 19of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Randomized,double-blind,
placebo-controlledstudyon65participants:
45depressedsubjectswithamean(±SD) Drowsiness,nervousness,anxiety,
ageof41(±13)years—17malesand fear,sadness,depression,nausea,
- 28females;and20HCwithamean(±SD) tremors,hotandcoldflashes, [102]
ageof39(±9)years—9malesand andmuscleaches
11females;administeredwith4×5mgof
yohimbinecapsules
Animalstudyon12maleSpragueDawley
Amitriptyline rats;administeredwith5mg/kgIPweekly Profoundhypothermia [103]
for6weeks
Animalstudyonsixunrestrainedbonnet Distresssymptoms,freezing
macaques(MacacaradiataÉ.Geoffroy); behaviors,clonicjawmovements,
- [104]
administeredwith0.10,0.25,0.50,or0.75 excessiveyawning,
mg/kg(0.93–9.74mg)ofyohimbineorally andsexualarousal
Randomizeddouble-blind
placebo-controlledstudyon53participants:
38subjectswithpanicdisorderswitha
mean(±SD)ageof35(±2)years—11males
Clonidine Anxietyandpanicattacks [105]
and27females;and15HCwithamean
(±SD)ageof30(±3)years—5malesand
10females;administeredwith0.4mg/kgof
yohimbineover10min
Casereportofanacuteyohimbine
intoxicationofadiabetic63-year-oldman;
Glyburide,alcohol took100×2mgofyohimbinetabletsin Anxietyandalertness [106]
about90–120min

## Page 20

Pharmaceuticals2020,13,309 20of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyonfourhealthyhorses—three
Agitation,musculartremors,
maresandonegelding;administeredwith
Tolazoline,xylazine 0.025mg/kgofyohimbineevery2minuntila mildexcitement,andreductionin [107]
maximaldoseof2.0mg/kg xylazine-mediatedsedation
Clinicalstudyoneightnarcoleptic
participants,fourmaleswithameanageof
43.5years(range22–64)andfourfemales
- Insomnia,tremors,andflushing [108]
withameanageof26years(range21–39);
administeredwith2.7,5.4mgofyohimbine
tabletstwicedailyupto16.2mg/day
Fourcasereportsofa44-,two45-,anda
Fluoxetine,TCAs,propranolol, Sexualarousal,sweating,shaking,
53-year-oldmaleswithPTSD;took“high” [109]
benzodiazepines panicattacks,andflashbacks
quantityofover-the-counteryohimbine
PETscansinasingle-blindfixed-orderstudy
onnineparticipantswithameanageof
30.7years—threemalesandsixfemales; Panicattack(onesubject)and
[15O]H 2 O administeredwith0.15mg/kguptoa increasedanxiety [110]
maximumdoseof10mgofyohimbineover
3min
Animalstudyon318maleOF1miceand
Blockageofopioid-mediated
Morphine,U-50,488,SNC80 maleSpragueDawleyrats;administered [111]
with2and4mg/kgofyohimbineIP spinalantinociception
Animalstudyonthreeadultmalerhesus IncreasedbindingpotentialforBDZ
benzodiazepines,[11C]flumazenil monkeys;administeredwith0.4mg/kg receptorsinthehippocampus [112]
ofyohimbine andanxiety
Randomized,double-blind,
placebo-controlledstudyon17participants:
8methadone-maintainedsubjectswitha Precipitationofwithdrawaland
- mean(±SD)ageof38(±2.6)years—6males cravingsymptomsin [113]
and2females;and9maleHCwithamean methadonepatients
(±SD)ageof30(±3.7)years;administered
with4mg/kgofyohimbineover10min

## Page 21

Pharmaceuticals2020,13,309 21of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyon73maleLong–Evansrats;
Xylazine,ketamine,buprenorphine, administeredwith1.25or2.5mg/kgof Reinstatementofextinguished
gentamicin,methamphetamine yohimbineIPafterextinctionand0.625mg/kg methamphetamineseekingbehavior [114]
after21–51daysofwithdrawal
Animalstudyon14adultsquirrelmonkeys
Cocaine,clonidine, (SaimirisciureusL.);administeredwith0.1and Reinstatementofextinguished
RS-79948,flupenthixol 0.56mg/kgofyohimbineIPbeforethe cocaineseekingbehavior [115]
reinstatementtest
Randomizeddouble-blindplacebo-controlled
studyon13maleparticipantswithamean
- (±SD)ageof24.9(±2.2)years;administered Increasedrestlessness,anxiety, [116]
with0.4mg/kgofyohimbineIV,procedure andimpairedmood
repeatedafter14days
SuppressionofP13andN40auditory
Animalstudyon12adultmaleSprague
circuitrycomponentsathighdoses
Pentobarbital Dawleyrats;administeredwith0.1,1.0, [117]
or10.0mg/kgofyohimbineIP andin
lo
c
w
re
/
m
m
e
o
n
d
t
e
o
ra
f
t
a
e
m
d
p
o
l
s
i
e
tu
s
deat
Casereportofanacuteyohimbine
intoxicationofa37-year-oldmalebody
Generalmalaise,vomiting,lossof
builder;took5gofyohimbine,foundwith
- 5240,2250,1530,and865ng/mLinblood3,6, consciousness, [118]
andtonic-clonicseizures
14,and22h,respectively,afteringestionand
50mg/Linurineatadmission
Randomizeddouble-blindplacebo-controlled
studyon24claustrophobicparticipants,
12yohimbine-receivingsubjectsand
Significantimprovementinpeakfear
12placebo-receivingpatients,79%females
- withamean(±SD)ageof24.46(±8.65)years attheone-weekfollow-up [119]
behavioralassessment
(malesnotreported);administeredwith
2×5.4mgofyohimbinepills,procedure
repeatedafter14days

## Page 22

Pharmaceuticals2020,13,309 22of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyon22maleSpragueDawley
Xylazine,ketamine,pentobarbital, rats;administeredwith1.25and2.5mg/kg Stressandreinstatementof
chloralhydrate,cefazoline, [120]
ofyohimbineIP30minbefore extinguishedheroinseekingbehavior
heparin,heroin
reinstatementsessions
Randomized,double-blind,
placebo-controlledstudyon24male
participants: 12athleteswithanaverage
- Anxiety [121]
ageof29yearsand12untrainedHCwith
anaverageageof29.5years;administered
with0.4mg/kgofyohimbineIV
Randomized,double-blind,
placebo-controlledstudyon35participants:
12acamprosate-receivingsubjectswitha
mean(±SD)ageof44.4(±1.6)
years—11malesand1female;
Nicotine,acamprosate Increaseinalcoholcravingsymptoms [122]
and13placebo-receivingpatientswitha
mean(±SD)ageof
44.1(±1.9)years—11malesand2females;
administeredwith0.4mg/kgof
yohimbineIV
Randomized,double-blind,
placebo-controlledstudyon22participants,
11patientswithIBSwithamean(±SD)age Increasedanxietyandreducedbrain
Clonidine, of40.5(±12.9)yearsand11HCwitha activityintheanteriorcingulate [123]
2-[18F]-fluoro-2-deoxy-D-glucose mean(±SD)ageof37.3(±10.6)years; cortex,amygdala,dorsalbrainstem,
andposteriorinsula
administeredwith40mgof
yohimbinetablet
Animalstudyon84Long–Evansjuvenile
Nicotine,ketamine,xylazine, rats;administeredwith0.3and0.6mg/kg Increasednicotineself-administration [124]
buprenorphine,bupivacaine,penicillin
ofyohimbineIPbeforeoperativesessions

## Page 23

Pharmaceuticals2020,13,309 23of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyon60rats(strainnot
reported);administeredwith1.25mg/kgof Increasedalcoholself-administration
Alcohol,d-PheCRF yohimbineIPbeforealcohol andreinstatementofalcohol [125]
self-administrationand seekingbehavior
reinstatementsessions
Twofatalcasereportsofacuteyohimbine
Caffeine,diphenhydramine,alcohol int f o o x u i n ca d ti 7 o 4 n 00 of n 2 g 3 / - m a L nd in 3 i 7 li - a y c ea b r l - o o o l d d a m n a d les; Seizures,elevatedvitals,anddeath [126]
5400ng/mLinheartblood,respectively
Animalstudyon193geneticallyselected
msPmalerats;administeredwith
Pioglitazone,naltrexone,alcohol 1.25mg/kgofyohimbineIP1hafter Reinstatementofalcohol [127]
seekingbehavior
naltrexoneandbeforethe
reinstatementsession
Randomized,double-blind,
placebo-controlledstudyon
119participants: 62cocaine-dependent
subjectswithamean(±SD)ageof41.1
Nicotine,caffeine, (±10.0)years—32malesand30females; Increaseinanxietyandcravingin [128]
and57HCwithamean(±SD)ageof33.1 cocaine-dependentsubjects
(±12.6)years—32malesand30females;
administeredwith21.6mgof
yohimbinecapsule
Animalstudyon768ABstrainwild
zebrafishlarvae,640yohimbine-receiving
- animals;administeredwith10,25,50,100, anxiogenicathighconcentrations [129]
or200mg/Lofyohimbinesolution,
and128HC
MDMA,SCH-23390,atropine,
A
r
n
at
i
s
m
;
a
a
l
d
s
m
tu
in
d
i
y
st
o
e
n
re
6
d
7
w
m
it
a
h
le
2
S
.0
p
m
ra
g
g
/
u
k
e
g
D
b
a
ef
w
o
l
r
e
e
y Anxiogeniceffectsandreinstatement
ketamine,xylazine reinstatementtestand5.0mg/kgdailyfor ofextinguishedMDMA [130]
seekingbehavior
10daysforchronictreatment

## Page 24

Pharmaceuticals2020,13,309 24of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Double-blind,placebo-controlledstudyon16
Agitation,restlessness,anxiety,
healthywomenagedbetween18and32years:
5yohimbine+naltrexone-receivingpatients, headaches,nausea,light-headedness,
vomiting,weakness,lethargy,
naltrexone and11-placebo-receivingpatients; [131]
tremors,blockageofanalgesiain
administeredwith16mgofyohimbineorally
ipsilateralforehead,andincreasein
aloneandco-administeredwith50mgof
electricallyevokedpaininforearm
naltrexoneorally
Randomized,double-blind,
placebo-controlledstudyon95participants:
39cocaine-dependentsubjectswithamean
(±SD)ageof41(±1.7)years—12malesand IncreasedimpulsivityinHCand
Nicotine,THC 27females;and56HCwithamean(±SD)age slowerhitreactiontimeinfemale [132]
of33(±1.7)years—32malesand34females; cocaine-dependentsubjects
administeredwith21.6mgofyohimbineprior
totwococaineexposuresessions
Randomized,double-blind,placebo-controlled
studyon103participantswithamean(±SD)
ageof24.79(±0.36)years—51malesand52 Decreasedmemorygeneralizationin
Hydrocortisone femalesrandomlyassignedtofour females(bothyohimbineand [133]
experimentalgroups(placebo,yohimbine, yohimbine+hydrocortisonegroups)
hydrocortisone,yohimbine+hydrocortisone);
administeredwith20mgofyohimbineorally
Randomized,double-blind,
placebo-controlledstudyon39participants:
13yohimbine-receivingpatientsand
10placebo-receivingpatients—13malesand
10femalesagedbetween18and52years; Nausea,headache,malaise,pain,
Naltrexone 5yohimbine+naltrexone-receivingfemales anxiety,andsexualarousal [134]
and11placebo-receivingfemalesaged
between18and32years;administeredwith
16mgofyohimbinealoneandco-administered
with50mgofnaltrexoneorally

## Page 25

Pharmaceuticals2020,13,309 25of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Randomized,double-blind,
placebo-controlledstudyon42health
participantswithamean(±SD)ageof21.29 Anxiety,nervousness,nausea,
(±3.27): 21yohimbine-receivingsubjects decreasedmotorandtemporal
- [135]
and21placebo-receiving impulsivity,andincreased
subjects—19malesand23females; reflectionimpulsivity
administeredwith20mgofyohimbine
orally45minbeforebehavioraltest
Alternated,double-blind,
placebo-controlledstudyon24participants
Alcohol,kavain(450.1mg/L), withameanageof26.7years Bodyswayanddecreasedreaction
dihydrokavain(456mg/L) (range=18–53),10malesand13females; timetasks [136]
12subjectsreceived500mLofkavajuice
and12receivedplacebo
Cross-overstudyon24participantswith
stress-inducedinsomnia,9maleswitha
meanageof43.7years(range23–65)and
Dizziness,vividdreams,
PipermethysticumG. Valerian 15femaleswithameanageof44.6(range [137]
anddrymouth
Forst. 30–65)years;administeredwith
120mg/dayofstandardizedkavaextract
for6weeks
Randomized,double-blind, Badtasteinmouth,difficulty
placebo-controlledstudyon38participants
achievingorgasm,drowsiness,
withaprevioushistoryofGADandamean
- (±SD)ageof51.7(±11.6)years—7males drymouth,increasedappetite, [138]
and31females;administered140mg/day muscletwitching,nausea,spasmsor
drawingofmuscles,sweating,
ofstandardizedkavaextractfor1week
and280mg/dayforthenext3weeks tinglingornumbness,andtrembling

## Page 26

Pharmaceuticals2020,13,309 26of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Slowsaccades,hypophonicspeech,
Casereportofakavaintoxicationofa generalizedposturalandtremorat
45-year-oldfemalewithafamilyhistoryof rest,severegeneralizedrigidityin
Benzodiazepines,fluoxetine,sertraline essentialtremor;took65mg/dayofkava axialandappendicularmuscles, [139]
extractfor10days severeakinesia,gaitdisturbancewith
lackofbalance,andinabilitytowalk
Randomized,double-blind,
placebo-controlledstudyon
141participantswithneuroticanxiety:
71subjectswithameanageof48.8(range
Withdrawal,aggravationof
- 18–69)years,administeredwith [140]
3×50mg/dayofstandardizedkavaextract anxiogenicsymptoms,andtiredness
for4weeks;and70placebo-receiving
subjectswithameanageof48.2(range
18–69)years—36malesand105females
Saccadeandcognitivestudyon28
participants: 11kava-intoxicatedsubjects
withamean(±SD)ageof38.1(±10.3)years Ataxia,tremors,sedation,
- and17kava-userswithamean(±SD)age disorientation,andblepharospasm [141]
of33.1(±7.0)years;took75–375gof
kavapowder
Randomized,prospective,openstudyon
68perimenopausalfemales:
15kava-receivingsubjectswithamean
(±SD)ageof51.5(±1.1)yearswere
administeredwith100mg/dayofcalcium
Kavain(55%) pluskavafor3months;19kava-receiving Nausea [142]
subjectswithamean(±SD)ageof
51.1(±0.8)yearswereadministeredwith
200mg/dayofcalciumpluskavafor3
months;and34HCwithamean(±SD)age
of50.2(±0.6)years

## Page 27

Pharmaceuticals2020,13,309 27of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyon40malesleep-disturbed
Hypnosis(shortersleeplatency,
Flunitrazepam,flumazenil Wistarrats;administeredwith10,30,or300 [143]
mg/kgofa96%ethanolkavaextract increaseinthetotalnon-REMtime)
Casereportofanacutekavaintoxicationof
Legweakness,severevertigo,nausea,
- a37-year-oldmale;tooka“toostrong” [144]
vomiting,diaphoresis,anddizziness
kavatea
Randomized,double-blind,
placebo-controlledstudyon24participants
HypericumperforatumL.,alcohol, withMDDandamean(±SD)ageof
caffeine 42.9(±8.8)years—20malesand38females; Onecaseofwithdrawal [145]
took3×2.66g/dayofherbalkavatablets
for10months
Randomized,double-blind,
placebo-controlledstudyon28participants
Dihydrokavain(26%),kavain(21%), withGADandamean(±SD)ageof30.1
dihydro ( m 14 e % th ) y , s y t a ic n in go ( n 18 in % ( ) 1 , 3 m % e ) t , hysticin ad (± m 1 i 2 n . i 4 s ) te y r e e a d rs w — it 7 h m 12 a 0 le a s n a d nd 24 2 0 1 m fe g m /d a a le y s o ; f diffi In c c u re lt a y s t e o d r f e e a m ch al t e h s e ’ o se rg x a d s r m iv i e n a m n a d les [146]
Desmethoxyyangonin(8%)
kavalactonesin3gtabletsofstandardized
extractofkavaroots
Randomized,double-blind,
placebo-controlledstudyon58participants
Dihydrokavain(26%),kavain(21%), withGADandamean(±SD)ageof30.1
dihydromethysticin(18%),methysticin (±8.8)years,20malesand38females; Significantreductioninanxietyand [147]
(14%),yangonin(13%), administeredwith120or240mg/dayof headaches
desmethoxyyangonin(8%)
kavalactonesin3gtabletsofstandardized
extractofkavaroots
Anxiolytics,antidepressants,
antinausea,antipsychotics,painkillers, Surveystudyon434participantswitha
stimulants,sedatives, mean(±SD)ageof34.54(±14.62)
meth/amphetamine,cannabis,cocaine, years—36.41%malesand63.59%females, Driving-impairment [148]
ecstasy,hallucinogens,opiates, 26kava-users
benzylpiperazine,syntheticcannabis

## Page 28

Pharmaceuticals2020,13,309 28of51
Table1. Cont.
Plant/Active
Co-Exposure Study,Participants,Age,andSex Neurological/PsychiatricEffects References
Ingredients
Animalstudyonadultwild-typeshort-fin
outbredzebrafishwitha1:1male-to-female
Kavalactones ratio;administeredwith10,20,or50mg/L Sedationandimmobility [149]
ofwaterextractfrompowderedkavaroots
for20minand7.5mg/Lfor1week
Animalstudyon18ADmodel
mice—12APP/Psen1strainand6wild-type
Methysticin DMSO mice;administeredwith6mg/kgof Reducedmovements [150]
methysticinonceaweekfor52weeks
AnimalstudyonCF1strainmaleadult
micepartedineightgroups
Diazepam,pentylenetetrazol Reducedlocomotion [151]
(15–30animals);administeredwith30,100,
Ptychopetalumolacoides or300mg/kgofethanolicextractfor30min
Benth.
Animalstudyon66CF1strainmaleadult
MK801,DMSO,scopolamine, albinomice;administeredwith50or Impairmentofbothshort-and
physostigmine 100mg/kgofstandardizedethanolicand long-termmemories [152]
100–800mg/kgonceadayfor21weeks
Randomized,double-blind, Headache,blurredvision,
placebo-controlledstudyon21participants poorhearing,nausea,vomiting,
Sceletiumtortuosum(L.) withamean(±SD)ageof54.6(±6.0), appetiteincrease,musclesrigidity,
- [153]
N.E.Brown 9malesand12females;administeredwith drowsiness,confusion,concentration
25mg/dayofstandardizedextract difficulty,memoryproblems,
®
(Zembrin )for3weeks depression,anxiety,andataxia
AD—Alzheimer’sdisease;ADHD—attentiondeficitandhyperactivitydisorder;ADD—attentiondeficitdisorder;BQ—betelquid;CA—Citrusaurantium;CNS—centralnervoussystem;
CPZ—cuprizone;EO—essentialoil;HC—healthycontrols;IBS—irritablebowelsyndrome;IP—intraperitoneally;IV—intravenously;MDD—majordepressivedisorder;MS—Mitragyna
speciosa;MSA—multiplesystematrophy;NAS—neonatalabstinencesyndrome;NPDS—UnitedStatesNationalPoisonDataSystem;PAF—pureautonomicfailure;PTSD—post-traumatic
stressdisorder; REM—rapideyemovement; SSRIs—selectiveserotoninreuptakeinhibitors; SNRIs—serotoninandnoradrenalinereuptakeinhibitors; ST—Sceletiumtortuosum;
SUD—substancesusedisorder;TCA—tricyclicantidepressant;TeCA—tetracyclicantidepressant.

## Page 29

Pharmaceuticals2020,13,309 29of51
3. Discussion
3.1. ArecacatechuL.(BetelNut)
Betelnutisoneofthemostwidelyusedaddictivesubstancesintheworldandrepresentsthefourth
mostconsumeddrugafternicotine,ethanol,andcaffeine[23,154]. Thefruit,obtainedfromthepalm
tree,ArecacatechuL.,iscommonlychewedinSoutheastAsiaandtheSouthPacificislands[155,156]
foritsantiparasitic,digestive,euphoric,andaphrodisiaceffects[157,158]. Therearetwomainways
to prepare areca nut for chewing: wrapping a split unripe nut with lime paste (calcium oxide)
inabeteltreeleaforinsertingapieceofPiperbetelL.inflorescencewithlimepasteintoanunripeareca
nut[22,154,159].
Thebetelnutcontainsavarietyofactivealkaloidsresponsibleforitseffects. Thecontentofmajor
alkaloidsarecoline,arecaidine,guvacoline,andguvacineinthefreshnutisapproximately0.30–0.63%,
0.31–0.66%,0.03–0.06%,and0.19–0.72%,respectively,althoughitmayvarywithmaturation[160–163].
Due to the presence of calcium oxide, arecoline and guvacoline are hydrolyzed to arecaidine and
guvacine,respectively,inbasicconditions[163,164]. Arecaalkaloidsmediatetheautonomicresponses
of the parasympathetic nervous system and the synaptic transmission in the peripheral nervous
system[164–166],andimpactvariousaspectsofbrainfunctionandregulation[167,168]. Arecolineis
apartialmuscarinic(M)agonistandpossessesahigheraffinityforMreceptorsthanguvacoline[24,169].
Higharecolinedosesproducenicotiniccholinergiceffects[170]. Astertiaryamines,arecolineand,
to a lesser extent, arecaidine have a deep brain penetration [165,169]. It was demonstrated that
arecolineenhancescognitionandmemoryandsignificantlyimprovesseveralbehavioraldisorders
in patients with Alzheimer’s disease or schizophrenia, through the activation of postsynaptic M1
receptors[24,162,171]. Inaddition,improvementsinpositiveandnegativesymptomsofpsychosis
have been observed in schizophrenic areca nut chewers [155,172,173]. It is believed that arecoline
reducesthedopaminergichyperactivityunderlyingthepositivesymptomsofpsychosisthroughout
themodulationofM1,M2,andM4receptors,andinducesdopaminereleaseintheprefrontalcortex,
the striatum, and the ventral tegmental area, ameliorating the negative symptoms [169,174,175].
Furthermore,thereleaseofdopamineandothercatecholaminescausesstimulantandlibido-enhancing
effects[3,156,166,176,177]. Theseeffects,coupledwiththeinhibitionofmonoamineoxidaseA(MAO-A)
causedbyaromaticphenoliccompoundsoftheplant,mayalsoexplaintheantidepressantproperties
ofthearecanut[24,169].
High betel nut doses can cause typical muscarinic and extrapyramidal symptoms such as
salivation,diaphoresis,diarrhea,gastrointestinalupset,emesis,vertigo,myosis,tremor,hyperthermia,
bradycardia,andasthmaattacks[156,158,166,168,176,178,179]. Furthermore,ifbetelnutistakenin
highquantities,transientextrapyramidalsymptomsincludingrigidity,bradykinesia,andjawtremor
mayoccur[24,176,180]. Theseeffectsareprobablyduetoguvacineandarecaidine,whicharestrong
inhibitorsofγ-aminobutyricacid(GABA)reuptakeandcontributetothereductioninspontaneous
activityandbodyexcitability[181–183]. However,itwasalsodemonstratedthatarecaalkaloidsreduce
GABAaffinityfortheGABA receptor,andarecaidineandguvacineeffectsonGABAsignalingmay
A
causeepilepticseizures[23,169,180,184]. Themainrisksassociatedwiththechronicconsumptionof
betelnutarerelatedtoitsmetabolism. Indeed,arecaalkaloidsareconvertedintoDNAalkylating
nitrosamines,whichcausecellproliferationandoxidativestress-dependentneurotoxicity,leadingto
oralcarcinogenicityandexacerbatingneurodegenerativediseasesymptoms[24,158,183,185]. Albeitits
useisculturallywellaccepted,thebetelnutisastronglyaddictivesubstanceandmultipleadverseeffects
werereported(Table1). Toleranceandnicotine/amphetamine-likewithdrawalsyndrome,characterized
byinsomnia,moodswings,irritability,andanxiety,mayappearafterrepeatedintakes[16,167,179].
3.2. CitrusaurantiumL.(BitterOrange)
CitrusaurantiumL.,alsocalledSevilleorange,sourorange,orbitterorange,isasmalltreebelonging
totheRutaceaefamily. ItisnativetoEasternAfrica,Arabia,andSyria,butisalsocultivatedinSpain,

## Page 30

Pharmaceuticals2020,13,309 30of51
Italy,andNorthAmerica[186]. Bitterorangetree’sleaves,flowers,fruitspeels,andseedshavebeen
usedforcenturiestotreattachycardia,rheumatism,insomnia,anxiety,epilepsy,andgastrointestinal
disordersandtoenhancesexualdesire[187–189].
Thebitterorangetreecontainsvitamins,minerals,terpenoids,andflavonoids[190]. Themost
abundant flavonoids are hesperetin and naringenin, which possess, together with terpenoids,
carotenoids,andascorbicacid,afreeradical-scavengingabilityandinhibitproinflammatorymediators
release, exerting a powerful antioxidant activity and reducing tumoral cell proliferation [191,192].
Terpenoidssuchasd-limonene,α-pinene,β-myrcene,linalylacetate,andlinaloolarethemainvolatile
components of the plant [193,194], and are distilled or extracted from blooms, leaves, and orange
peel to obtain essential oils (EOs) [195]. These substances, especially d-limonene, modify the cell
membrane of microbes and denature enzymes responsible for their germination and sporulation,
showingantimicrobicandantifungalproperties[191,196]. Forthesereasons,bitterorangetree’sEOs
arewidelysoldasflavoringandpreservativeagentsinfoodsanddrinks[190,197]. Recently,agreat
interestintheseEOshasbeenobservedinthecontextofalternativemedicinessuchasaromatherapy.
Itwasdemonstratedthatthesesubstances,aftervaporizationandinhalation,areeffectivefortreating
differentformsofanxiety, sleep, andlibido, andreduceseizuresinanimalmodels[38,39,198–201].
Themechanismofactionoftheplant’singredients,however,isnotfullyelucidated. Anxiolyticand
hypnoticeffectsareseeminglyduetothecombinationoftheactionoftheplant’saromaonthelimbic
systemthrougholfactionandthedirectactionofterpenesonGABAergicandserotoninergic(5-HT )
1A
receptors[39,202,203].
Adverse effects are mild and transient; psychiatric and neurological effects are reported in
Table 1. The US Food and Drug Administration confirmed that oral administration of bitter orange
extractsissafe[39],anditsderivativeshavegainedpopularityasdietarysupplementsoverthelastfew
years [200,204]. Standardized derivatives containing 4–6% synephrine, an ephedrine-like alkaloid
naturallyoccurringinC.aurantiumandpossessingα-andβ-adrenergicproperties,areavailable[3,40,205].
Although synephrine has become one of the most popular stimulants in weight loss products,
cardiovascularadverseeffectsincludingincreasedbloodpressure,tachycardia,ventricularfibrillation,
transientcollapse,myocardialinfarction,andcardiacarresthavebeenreported[206]. Headacheand
gastrointestinalsymptomshavealsobeenreported.
3.3. MitragynaspeciosaKorth. (Kratom)
KratomisanherbalpreparationobtainedfromtheleavesofMitragynaspeciosaKorth,anevergreen
plantoftheRubiaceaefamilythatgrowsspontaneouslyinSoutheastAsia, mainlyinThailandand
Malaysia[207]. Inthesecountries, theplanthasbeenexploitedforcenturiesforitsstimulantand
narcoticpropertiesandiscommonlyself-administratedbymanuallaborerstocombatfatigueand
improveproductivity[51]. Mitragynaleavesaretraditionallychewed,smoked,orboiledwithhot
water and served as a tea [208]. New preparations such as capsules, resins, or tinctures are now
availableontheInternetandarepurchasedinEuropeandinAmericaforrecreationaluseorasherbal
products[209,210].
Morethan40alkaloidswereisolatedfromkratom. Thealkaloids’contentisvariableanddepends
on plant age, season, and geographical location [211]. Mitragynine is the most abundant active
compound and accounts for up to 66% of the total mass of crude alkaloids extract. Other major
alkaloids are paynantheine, which is the second most abundant alkaloid (10% of total content),
speciogynine,andspeciociliatine. Amongthevariousminoralkaloids,7-hydroxymitragynineisof
particular interest due to its important role in mediating the analgesic effect of mitragynine [157].
Bothmitragynineanditsoxidizedmetabolite7-hydroxymitragyninearepartialagonistsofµ-opioid
receptors(MOR)andcompetitiveantagonistsofκ-andδ-opioidreceptors(KORandDOR),whichare
involved in analgesia. However, mitragynine affinity for opioid receptors is lower than that of
morphine,while7-hydroxymitragynineaffinityisapproximately46and13timeshigherthanthatof
mitragynineandmorphine,respectively[212]. Thepossiblestimulantandlibido-enhancingeffects

## Page 31

Pharmaceuticals2020,13,309 31of51
ofmitragyninemaybeduetotheblockadeofserotonergic5-HT receptorsandthepostsynaptic
2A
stimulationofα adrenergicreceptors(α R)intheCNS[212]. Recently,LaBryeretal. hypothesized
2 2
thatkratommayhaverestoredtestosterone,luteinizinghormone(LH),follicle-stimulatinghormone
(FSH),andprolactinlevelsinapatientwithhypogonadotropichypogonadism[213]. Mitragynine
also binds adenosine A receptors, dopamine D receptors, and serotonin receptors 5-HT and
2A 2 2C
5-HT , but the physiological significance of these interactions is unclear [214]. Data showed that
7
lowkratomdoses(1–5g)inducestimulatingeffects, involvingthereleaseofneurotransmittersby
reversibleblockadeofcalciumchannels. Athigherdoses(>15g),itcancausesedative/narcoticeffects,
andtheplantcanbeusedasageneralanalgesic,asanopiumsubstitute,ortotreatopiumwithdrawal
symptoms[215].
Studieshavefoundthat7-hydroxymitragynineisthemaincontributortotheplant’stoxicityand
thedevelopmentofaddictionsymptoms. In2014,Singhetal.[51]reportedacross-sectionalsurvey
investigatingthecorrelationbetweenfrequencyandquantityofkratomconsumption,andtheriskof
addictiondevelopmentandtheseverityofwithdrawalsymptomsandcravinginregularuser[216].
Cessationofkratomuseproducedphysicalwithdrawalsymptomssimilartothoseofopiateaddiction
includingpain,sleepdisorders,musclespasms,wateryeyes,runnynose,hotflashes,fever,decreased
appetite, diarrhea, and craving. Psychological withdrawal symptoms reported by users included
restlessness,tension,anger,anddepression[217](Table1).
3.4. PanaxginsengC.A.Mey(AsianGinseng)andPanaxquinquefoliusL.(AmericanGinseng)
GinsengisaperennialherbaceousplantofthefamilyAraliaceae. Overtwelveginsengspecieswere
identified,althoughmainlyAsianorKoreanginseng(P.ginseng)andAmericanginseng(P.quinquefolius)
have been used for their therapeutic properties. Asian ginseng grows in East Asian mountains,
whileAmericanginsengisanendangeredspeciesthatgrowsindeciduousforestsofthewesthalf
of North America. Asian ginseng is an emblematic plant of traditional Chinese medicine, and is
listedintheShennongBenCaoJing,themostancientChinesebookofherbalmedications. Avariety
ofpharmacologicaleffectsareattributedtoginseng. Forexample,itisusedtoimproveintelligence,
totreatimpotence,totreathemorrhage,torelax,andtoslowaging[218]. Americanginsengmedical
useismorerecentandhasgainedpopularityinWesterncountriesoverrecentdecades. Ginsenghealth
benefits were demonstrated in many clinical studies in various fields: it has shown aphrodisiac,
anti-inflammatory, anticancer (lung, liver, intestine, and stomach), antidiabetic, cardioprotective,
gastroprotective,antiamnestic,andantioxidative(heartandkidney)properties[219]. Thefreshrootof
ginsengcanbedirectlychewedafterpeelingorsoakedinwinefordrinkingandchewing. InChina
andKorea,itisboiledwithchickentoprepareenergydrinks,teas,andcandies[218].
AsianandAmericanginsengcontainavarietyofpharmacologicallyactivetriterpenesaponins,
namedginsenosides. Ginsenosidesareclassifiedintotwogroupsdependingonthehydroxylation
of their steroid core structure: the 20(S)-protopanaxadiol (PPD) and 20(S)-protopanaxatriol (PPT)
groups. Rb1, Rb2, Rb3, Rc, and Rd are the main PPD-type ginsenosides, and Rg1 and Re are the
mainPPT-typeginsenosides. Atotalof32ginsenosides,includingtheabovementionedcompounds,
arefoundininbothAmericanandAsianginseng,butthetwoplantsalsopossessspecificginsenosides.
ThepresenceofRf,aPPD/PPTratiolowerthan2,andaRb1/Rg1ratiolowerthan5usuallyidentifyAsian
ginseng. Thecontentofginsenosidesisaffectedbyseasons,geographicaldistribution,andprocessing
(fresh ginseng, steamed ginseng or white ginseng, and sun-dried ginseng or red ginseng) [220].
Afteroraladministration,ginsenosidesaremainlymetabolizedinthegastrointestinaltractandthe
liver,undergoingsuccessivedeglycosylations: Rg3isametaboliteofRb1,Rb2,Rb3,Rc,andRd,andis
furthermetabolizedtoRh2;Rg2isametaboliteofRe;andRh1isametaboliteofbothRg1andRg2.
Ginsenosides have low oral bioavailability, owing to their low membrane permeability and their
degradation in the gastrointestinal tract [219]. Rg1 induces NO synthesis in endothelial cells and
perivascularnerves,andincreasesvascularsmoothmusclesensitivitytoNO,prolongingtheerection
inmalesandenhancingsexualpotency. Inaddition,P.ginsengwasprovedtoincreasetestosterone,

## Page 32

Pharmaceuticals2020,13,309 32of51
LH,andFSHinhealthyvolunteersthroughRg1andRb1,enhancinglibido. Reincreasesextracellular
dopamineandacetylcholineinratbrains,whileRb1increasescholinereuptakeatthesynapses. Rb1,
Rb2,Rc,Re,Rf,andRg1areagonistsofGABA receptorsandRcisalsoanagonistofGABA receptors.
A B
Thesemodulationsofseveralneurotransmissionpathwaysmayhaveaneffectatdifferentlevelsofthe
hypothalamus–pituitary–testisaxis[221]. MancusoandSantangelorecentlyreviewedtheeffectsof
ginsenosidesontheimmunesystem(e.g.,modulationoftheimmuneresponse,anti-inflammatory
effects),thenervoussystem(e.g.,regulationofthestressaxis,improvementofmemoryandlearning
functions),andthecardiovascularsystem(e.g.,improvementofcardiacperformance,cardioprotective
effects)[222].
AmericanandAsianginsengpresentagoodsafetyprofilewithafewcasesofmildgastrointestinal
and sleep disorders. Psychiatric and neurological side effects are rare, and causality is difficult to
ascertain[77,79,80,82–87,89–94]. Infact,mostclinicalstudieswithginsengorginsenosidesreportedno
psychiatricorneurologicalsideeffectsorstatisticallyinsignificanteffectscomparedtoplacebo,andwerenot
includedinTable1[223–227]. Afewcasesofheadachefollowingginsengadministrationwerereported
withoutplacebocontrol[84,91]. Insomnia,agitation,andfatigueweremorefrequent[82–84,89,94],butstill
uncommon. Moreinterestingly,severalcasesofmanic-likeeffects,suchasconfusion,agitation,irritation,
nervousness, anxiety, andbizarrebehavior, withouthistoryofpsychiatricdisorder, werereported
followingginsenguse[77,78,81,85,87,88,90,228]. Thesecases,however,wereisolatedandgenerally
resultedfromhighginsengdosesorwiththeconcomitantuseofothersubstances(e.g.,phenelzine,
cannabis,herbalsupplements);maniawasnotreportedinclinicalstudiesusingginsengaloneorin
combination. Infact,ginsengtoxicitymainlycomesfromdruginteractionswithcytochromesP450
(CYPs) CYP3A4 and CYP2D6 inhibitors and serotoninergic drugs, intensifying sedative effects or
inducingcognitivedisordersoraserotoninsyndrome[229–231].
3.5. Pausinystaliajohimbe(K.Schum.) PierreexBeille(Yohimbe)
Pausinystaliajohimbe(K.Schum.) PierreexBeille,alsoknownasyohimbe,isanevergreentreeof
theRubiaceaefamilythatmainlygrowsinthetropicalregionoftheAfricanWestcoast,wherethebark
hasbeenconsumedasanaphrodisiacforthetreatmentoferectiledysfunction[157,232].
Thebarkoftheplantcontainsseveralstructurallyrelatedindolealkaloids,yohimbinebeingthe
mostabundantone(10–15%oftotalcontent),followedbyitsstereoisomersα-yohimbine,β-yohimbine,
ψ-yohimbine,corynanthine,allo-yohimbine,andyohimbicacid[233,234]. Yohimbineismarketedas
apharmaceuticalprescribedforthetreatmentoferectileimpotenceandhasbeenusedinmultiple
clinical trials as a probe to identify abnormal physiological and affective responses to increased
noradrenergicsignaling,especiallyinpatientswithpanicdisorders[235,236]. Yohimbineisapotent
selectiveα Rantagonistwithweakerα Rantagonistactivitythatblocksthepresynapticfeedback
2 1
inhibitionofnoradrenalinerelease,prolongingtheexcitatoryeffectsofnoradrenalineatpostsynaptic
α Randβ-receptors[237,238]. Yohimbinehasarelativelyshorthalf-lifeduetoanextensivehepatic
1
metabolism, which produces two main hydroxylated metabolites, 11- and 10-hydroxyyohimbine,
thatarerapidlyexcretedinurine[239,240]. Thereisincreasinginterestinbotanicdietarysupplements
containingyohimbineextractsinthecontextofsexualandbodyenhancement[241].
Yohimbine readily passes the blood–brain barrier after absorption, causing an increase in
sympathetictoneandbloodpressurethroughtheblockadeofcentralmedullaryα R[242],andprovokes
2
noradrenergicperturbationinlimbicforebrainstructureslikeamygdalaandlocuscoeruleus,leadingto
moodandbehavioralterations(Table1). Duetothesepotentialcardiacandneurologicaladverseeffects,
yohimbinewasusedinpatientswithdifficultiestoreachorgasm,witherectiledysfunction,orwith
lowlibido,mainlybeforetheemergenceofphosphodiesterase5(PDE5)inhibitors(e.g.,sildenafil),
whichpresentabettersafetyprofile[243,244]. Theyohimbinemechanismofactioniscurrentlyunclear.
Thereisevidencesuggestingthatyohimbineincreaseslibidobyblockingα Rinthelocuscoeruleus,
2
whichisinvolvedinthecontroloftheerection. Peripherally,itwassuggestedthatyohimbineenhances
NO release from cavernosal endothelial cells, producing a relaxation of smooth muscle cells and

## Page 33

Pharmaceuticals2020,13,309 33of51
consequent erection, increasing sexual potency [3,6,237]. Moderate to severe adverse effects like
sweating, flushing, hypertension, tachycardia, palpitations, bronchospasm, chest pain, and atrial
fibrillationarereportedafterdeliberateoraccidentalingestion,whilelethalintoxicationsareextremely
rare[245,246].
3.6. PipermethysticumG.Forst. (Kava)
NativetoWesternPacificislandswheretheshrubistraditionallycalled“ava”,“wati”,or“yagona”,
kava(PipermethysticumG.Forst)growsinhumidandshadedareasoftropicalregions. Thisisaperennial
Piperaceae with a massive rhizome weighing up to a dozen kilograms [19]. Kava is considered as
asacredbeverageinPacificislands[247]. Theplanthasalsobeenusedintraditionalmedicine,firstas
atreatmentforvenerealdiseases,thenlaterasasedativeandtreatmentforanxietyandsleepdisorders,
todecreasefatigue,andtorelievepain[248].
Eighteen active compounds named kavalactones were identified in kava, but only six,
i.e.,methysticin,dihydromethysticin,kawain,dihydrokawain,desmethoxyyangonin,andyangonin,
havebeenthefocusofkavastudiesastheyaccountforupto96%oforganicextracts(acetonicorethanolic
extraction). Kavaalsocontainsavarietyofothernon-lactonecompounds,i.e.,flavokawainsA,B,andC,
5,7-dimethoxyflavanone,cinnamicacidbornylester,flavanones,fattyacids,andachalcone. Kavaeffects
maybetheresultofasynergyofthesixmajorkavalactones[249]. Kavaextractsproduceasimilaractivity
profileasthatofbenzodiazepines,whichinteractwithGABAreceptors,inhibittheMAO-B,andinhibit
dopamineandnoradrenalinereuptakeintheCNS,inducinglibido-enhancingproperties[250]. Invitro
studiesofthehippocampusandotherbrainregionssuggestthatthesedativeeffectsofkavalactonesmay
bemediatedbyanincreaseinGABA receptorbindingsites[251,252]. Itwasdemonstratedthatseveral
A
kavalactonesarepotentinhibitorsofseveralCYPmetabolicenzymes[253]. Oralpharmacokinetics
ofkawain(100mg/kg)weredeterminedinratswithandwithoutco-administrationofkavaextract
(256mg/kg). Theresultsshowedthatkawainwaswellabsorbed,andmorethan90%ofthedosewas
eliminatedwithin72h,mainlyinurine[254].
Dataonkava’ssafetyprofileobtainedfromclinicaltrialsinpatientswithanxietysuggestgenerally
goodtolerabilityandsafetyforshort-termuse(1–4weeks)attherapeuticdoses. However,theuse
of kava at frequent and high doses can cause hepatotoxicity through the modulation of various
CYP, which is also the cause of potential drug interactions [255], dermopathy [256], and cognitive
disorders[257]. Sedationwithdrowsinessanddizzinessiscommonlyreportedinclinicaltrialswith
administrationofkavaormethysticin(Table1),whichmayimpairdrivingperformances[148].
3.7. PtychopetalumolacoidesBenth. (Muirapuama)
PtychopetalumolacoidesBenth. isapopularAmazoniantreebelongingtotheOlacaceaefamily. Itis
alsoknowninBrazilasmarapuamaormuirapuama[258]. Thenativecommunitieshaveuseditsroots
andbarksasatreatmentfordepression,sexualdysfunction,andasa“nervetonic”[259]. Rootsare
usuallypreparedinalcoholicinfusion,butotherformulationshavealsobeenemployed(e.g.,mixture
ofextracts,solutions,pills)[260].
Muirapuama root bark produces a volatile oil containing α-pinene, α-humulene, β-pinene,
β-caryophyllene, camphene, and camphor. Fatty acids such as uncosanoic, tricosanoic,
andpentacosanoicacidsaccountforupto20%ofthetotallipophiliccomponentsoftheplant[261].
Othercompoundsdetectedinmuirapuamaarefattyacidestersofsterols,coumarin,freefattyacids,
andfreesterol;asmallquantityofβ-sitosterolwasalsodetected[262]. Basedonethnopharmacological
data,itcanbehypothesizedthatmuirapuamainteractswiththedopaminergicsystem,increasinglibido;
thenoradrenergicsystem,inducingantidepressanteffects;andtheserotonergicsystem,modulating
appetite. Theantinociceptiveeffectsoftheplantwereinvestigatedinthermalandchemicalmodels
ofnociceptioninmice. Datashowedthatthemaximaleffectwasreached6hafteradministration
ofalowdoseofmuirapuamaextractandproducessignificantandlong-lasting(up12h)effectsin
bothchemicalandthermaltestsofnociceptioninmice. Inaddition,higherdoses,eitheracutelyor

## Page 34

Pharmaceuticals2020,13,309 34of51
subchronically(15days),didnotcauseaworseningofadverseeffects[263]. Afewneurologicalside
effectswerereportedinpreclinicalstudies,includingimpairmentofbothshort-andlong-termmemory
andreducedlocomotion[151,152](Table1).
3.8. Sceletiumtortuosum(L.)N.E.Brown(Kanna)
Kanna,orChanna,isthetraditionalnameofasucculent,perennialplantbelongingtotheAizoaceae
family(earlierMesembrynantheaceae)thatisindigenoustoSouthAfrica,whereitisconsumedbylocal
tribestorelievethirstandhungerandcombatfatigue[264,265]. Thedriedaerialpartsoftheplant
are commonly chewed or consumed as teas, decoctions, and tinctures and sometimes smoked or
snuffed[266].
Kanna’s main active compounds are mesembrine, mesembrenol, mesembrenol,
andmesembrenone,whicharesynthesizedintheplantthroughthecondensationofphenylalanine
and tyrosine amino acids. Kanna alkaloids inhibit serotonin reuptake and PDE4A, potentially
enhancing sexual potency and libido [267–269]. In fact, the plant is widely sold over the Internet
and specialized herbal shops to increase sexual performance, although its mechanism of action
and effects were not clearly demonstrated. This dual inhibitory effect has been studied for the
developmentofcompoundsforthetreatmentofcognitionimpairment,motordysfunction,depression,
andneurodegeneration[270]. MesembrenoneisthemostpotentinhibitorofPDE4A,whilemesembrine
ismoreselectivetowardstheserotoninreceptor. Inaddition,mesembrineisalsoanagonistofGABA ,
A
δ -opioid, µ-opioid, cholecystokinin-1, E4-prostaglandin, andmelatonin-1receptorsathighdoses,
2
andshowsantinociceptiveeffectsinanimalmodels[266,270–273]. Recently, S.tortuosumhasbeen
®
marketedforthetreatmentofmilddepressionandtoimprovemood[274]. Zembrin ,astandardized
hydroalcoholic extract, was found to be safe and well-tolerated in preclinical studies with mild
adverse effects (Table 1) and is widely sold as a dietary supplement [275]. Another commercially
availableproductisTrimesemine™,ahighly-concentratedmesembrineextract(3%mesembrine(w/w))
thatshowsagreatupregulationoftheexpressionofvesicularmonoaminetransporter-2(VMAT-2),
increasingmonoaminesreleaseastheprimarypharmacologicaleffect[276,277]. Kannaalkaloidsare
metabolizedinthelivertoO,N-demethylatedordehydroxylatedcompounds,whicharethenexcreted
asglucuronidesorsulfatesconjugates[277,278].
3.9. OtherPlants
Little evidence was found on the psychiatric and neurological side effects of several sexual
enhancersthatwereoriginallyincludedinthisreview: A.Mexicana,E.longifolia,L.meyenii,T.diffusa,
V.africana,andW.somnifera.
The safety of maca (Lepidium meyenii Walp.) and ashwagandha or Indian ginseng
(Withania somnifera (L.) Dunal) is well-documented. Maca is an edible herbaceous plant of the
AndesMountainsandhasbeenusedforcenturiesforimprovingmaleandfemalesexualfunction.
Arenewedinterestformacahasbeenobservedfromthe1990sonwards,andpills,capsules,flour,
liquor,andextractsarenowmassivelyproducedandexported[279]. Theplant,however,presentsa
goodsafetyprofile[279],andonlyonecaseofamanic-likeepisodefollowingconsumptioninapatient
withouthistoryofpsychiatricdisorderswasreported[280]. Ashwagandhaisanevergreenshrubof
thefamilySolanaceae,whichiscultivatedinhotanddryareasoftropicalandsubtropicalregionsof
theworld. AshwagandhahasnumerousapplicationsintraditionalIndianmedicinesandhasbeen
usedformorethan5000yearsasanaphrodisiac,antioxidant,antimicrobial,adaptogenic,diuretic,
tonic, narcotic, immuno-stimulant, anti-inflammatory agent, anti-stress, antiulcer, among many
other purposes. Positive effect in insomnia, anxiety, chronic stress, weight management, thyroid
gland function, telomerase, cardio-respiratory endurance, muscle strength, recovery of male and
female sexual function, and senescence was demonstrated in preclinical and clinical studies [164].
Excellenttolerabilityisgenerallyreportedafterusingashwagandhaforweeksattherapeuticdoses,
withstatisticallyinsignificantadverseeffectscomparedtoplacebo[281,282].

## Page 35

Pharmaceuticals2020,13,309 35of51
Other plants have been little studied, although some of them are well-known remedies that
havebeenusedformanyyears. Furtherinvestigationisnecessarytoclearlyunderstandthepossible
neurologicalandpsychiatriceffectscausedbytheseplants. Forexample, damiana(Turneradiffusa
Willd. Ex. Schult.),aCentralAmericanshrubofthefamilyPassifloraceae,hasbeentraditionallyusedfor
centuriesasastimulantandaphrodisiac,tosparkmalesexualdriveandincreaseperformance,andisstill
widelymarketed[283]. Recently,theplantalsoprovedtoinduceanxiolyticandantidepressanteffects
inpreclinicalstudies[283,284]. However,nopsychiatricorneurologicalsideeffectsrelatedtodamania
werereported. AnotherinterestingexampleisVoacangaafricanaStapfexScott-Elliot,ashrub/smalltree
oftropicalAfricawhoseseedshavebeenrecentlycommercializedasapoison,stimulant,aphrodisiac,
andceremonialpsychedelic[285]. Althoughtheplantcontainsavarietyofindolealkaloidsrelatedto
ibogaine,awell-knownpsychoactivesubstancefromiboga(TabernantheibogaBaill.) thathasalsobeen
usedasanaphrodisiac[286],thereisnoevidenceofpositiveeffectsonsexualfunction. Inaddition,
althoughVoacangaafricanaalkaloidsmaymodulateneuronalexcitabilityandhavepositiveeffectsin
Alzheimer’sdisease[287,288],noneurologicalorpsychiatriccomplicationsrelatedtotheplantwere
reported. ThereisalsolittleinformationonthesideeffectsoftheMexicanpoppy(ArgemonemexicanaL.)
andTongkatAli(EurycomalongifoliaJack.).
Otherherbalaphrodisiacsthatwerenotincludedinthisliteraturereviewarecommonlyused,
butdataontheirsafetyprofilearealsolimited[14].
3.10. GeneralDiscussion
Thepsychiatricandneurologicalsideeffectscausedbytheconsumptionofherbalaphrodisiacs
aremild,withmostlynoconsequencesattherapeuticdoses. Althoughrare,psychiatricsideeffects
weremostlyreportedandincludedanxiety,depression,psychosis,andmania. Neurologicaleffects
included seizures, extrapyramidal symptoms, and withdrawal symptoms. Dizziness, sleepiness,
fatigue, agitation, insomnia, and headaches were reported. As expected, all the plants involved
are libido-enhancing aphrodisiacs altering neurotransmission, although ginseng (P. ginseng and
P. quinquefolius) and yohimbe (P. johimbe), and kanna (S. tortuosum) also enhance sexual potency.
Kratom(M.speciosa)andyohimbepresentedthehighestrateofsideeffects,butyohimbe’sgeneral
toxicity is mainly cardiovascular, due to its effects on the NO pathway. These mild effects were
not anticipated, considering the mechanism of action of these plants. However, they did not
come as a complete surprise, because these plants have been used for centuries or millennia in
traditionalmedicinesandmodernmedicinehasconsiderablybenefitedfromtheseingredientsand
preparations[289].
Fewclinicalreportsandfewdatawerefoundforthesideeffectsofbitterorange(C.aurantium),
muirapuama (P. olacoides), and kanna (S. tortuosum), and only preclinical reports were found for
muirapuama. Therewerenoreportsonthesideeffectsofdamania(T.diffusa),theMexicanpoppy
(A. mexicana), and Tongkat Ali (E. longifolia). Although several of these plants have been used for
centuries in traditional medicines, they have not been as extensively studied as the other plants
includedinthisreview. Therefore,thisresultwasnotsurprising. Psychiatricandneurologicalside
effectsincludedheadachesandhypnoticeffectsandweremild. Althoughtheconsumptionofthese
plants appears safe, further studies should be conducted to better understand their positive and
negativeeffects.
Herbal aphrodisiacs are readily available on the Internet and specialized shops and markets.
Asidefromsexualenhancement, theseplantsoftenhavemanyothertherapeuticapplicationsand
can be a part of the everyday diet of individuals. In addition, self-medication is frequent, as they
areavailablewithoutaprescription,andplantextractsprovidedbyretailherbalstoresmayalsobe
mislabeled or adulterated (e.g., heavy metals, pharmaceuticals) [290]. Consequently, these plants
areoftentakenconcomitantlywithcontaminants,medications,andotherherbaltherapiesordietary
supplements: druginteractionsrepresentthemostsignificanthealthrisksofherbalaphrodisiacsand
psychiatric and neurological adverse effects have been reported [230]. Medical doctors should be

## Page 36

Pharmaceuticals2020,13,309 36of51
awareofthepotentialdruginteractionswithaphrodisiacsanddietarysupplementswhenprescribing
apharmaceuticaldrug.
3.11. Limitations
Consideringthepaucityofdataandthefrequentco-exposuretootherpsychoactivesubstances,
conclusionscanbehardlydrawnregardingthepsychiatric/neurologicaladverseeffectsofseveralof
theplantsincludedinthisarticle. Inparticular,moreclinicalstudieswithcontrolledadministrations,
tohaveabettergraspondosesandco-exposures,shouldbeconductedtoaddressthisissue.
Anotherlimitationisthechoiceofthekeywordsusedfortheliteraturesearch. Thereviewfocused
onselectedplantsandtheiractiveingredients,whichwereincludedafterapreliminaryscreeningof
theliterature. Otherlesscommonherbalaphrodisiacsmighthaveeludedthesearch.
Additionally,onlyarticleswritteninEnglish,Italian,andFrenchwereincludedinthereview,
and reports written in another language were excluded. This limitation is particularly relevant
consideringtheprevalenceoftraditionalAyurvedic,Unani,andChinesemedicinesinEastAsiaand
diasporas[291].
4. MaterialsandMethods
AcomprehensiveliteraturesearchwasconductedusingthePubMed,Scopus,andWebofScience
bibliographicdatabasestoidentifyscientificreportsonthepsychiatricandneurologicalcomplications
associatedwiththeuseofA.catechu, A.mexicana, C.aurantium, E.longifolia, L.meyenii, M.speciosa,
P. ginseng, P. quinquefolius, P. johimbe, P. methysticum, P. olacoides, S. tortuosum, T. diffusa, V. africana,
andW.somnifera. Database-specificsearchfeatureswithtruncations(representedbyanasteriskin
thisarticle)andmultiplekeywords(representedbyquotationmarksinthisarticle)wereemployed.
Thesearchtermsemployedwereaddict*,anxiety,anxious,“braindisorder*”,cognit*,depression,
depressive,hallucin*,insomnia*,mania*,manic,mental,panic,“personalitydisorder*”,psychiatry*,
psychosis,psychotic,orschizoph*incombinationwiththefollowingtermsforeachplant:
• A. catechu: “Areca catechu”, “areca palm”, “areca nut palm”, “betel palm”, “Indian nut”,
“Pinangpalm”,arecaidine,orarecoline;
• A. Mexicana: “Argemone mexicana”, “Mexican poppy”, “flowering thistle”, sanguinarine,
dihydrosanguinarine,dehydrocorydalmine,jatrorrhizine,columbamine,oroxyberberine;
• C. aurantium: “Citrus aurantium”, “bitter orange”, “Seville orange”, “bigarade orange”,
or“marmaladeorange”;
• E. longifolia: “Eurycoma longifolia”, “tongkat ali”, “pasak bumi”, “Malaysian ginseng”,
eurycomanol,eurycomanone,oreurycomalactone;
• L.meyenii: “Lepidiummeyenii”,maca,or“Peruvianginseng”;
• M.speciosa: “Mitragynaspeciose”,kratom,biak,mitragynine,orhydroxymitragynine;
• P.ginsengandP.quinquefolius: “Panaxginseng”,“Panaxquinquefolius”,ginseng,orginsenoside*;
• P. johimbe: “Pausinystalia johimbe”, yohimbe, ajmalicine, allo-yohimbine, corynantheine,
pseudoyohimbine,raubasine,yohimbine;
• P.olacoides: “Ptychopetalumolacoides”,“muirapuama”,ormuirapuamine;
• S. tortuosum: “Sceletium tortuosum”, kanna, channa, kougoed, mesembrine, mesembrenone,
mesembrenol,ortortuosamine;
• T.diffusa: “Turneradiffusa”,damania,ordamianin;
• V.Africana: “Voacangaafricana”,voacamine,orvoacangine;
• W.somnifera: “Withaniasomnifera”,ashwagandha,“Indianginseng”,or“poisongooseberry”.
Further studies were retrieved from the reference list of selected articles and reports from
internationalinstitutionssuchastheWorldHealthOrganization(WHO),theUSDrugEnforcement
Administration(DEA),andtheEuropeanMonitoringCentreforDrugsandDrugAddiction(EMCDDA).

## Page 37

Pharmaceuticals2020,13,309 37of51
Recordsreportingthepsychiatricand/orneurologicaladverseeffectsassociatedwiththeuseof
theselectedplantspeciesinhumanswereincluded;onlyarticleswritteninEnglish,French,andItalian
were included. Databases were screened up until June 2020 and references were independently
reviewedbythreeoftheauthorstodeterminetheirrelevancetothepresentarticle.
5. Conclusions
Most of the sexual enhancers of plant origin included in this review appeared to be safe at
therapeuticdoses,andfewpsychiatricandneurologicalsideeffectswerereported. Yohimbemainly
wasinvolvedinintoxicationcases,butitscardiovasculartoxicityismoreconcerningthanitspsychiatric
andneurologicaladverseeffects. Inaddition,causalitywasoftendifficulttodetermine,especiallyin
casereportsandself-reports,inwhichco-administrationofothersubstancesandherbalformulations
isprevalent. Interactionswithpharmaceuticalsorotherherbalsupplementsaremorecommonand
mayposeasignificanthealththreat.
The mechanisms underlying psychiatric and neurological disorders are multifaceted,
often involving multiple CNS pathways and receptors, and are not fully understood. Similarly,
herbal aphrodisiacs often contain multiple active ingredients with multiple mechanisms of action
thatareyettobefullycharacterized. Consequently,themechanismsunderlyingthepsychiatricand
neurologicalsideeffectsassociatedwithherbalaphrodisiacuseislittle-known.
OthersourcesofaphrodisiacsaffectingtheCNSareavailable,suchassyntheticorsemi-synthetic
drugsandnaturalsubstancesofanimalorigin,whichmayalsoinducepsychiatricorneurological
effects. Although aphrodisiacs are mainly obtained from plants, these substances may also be
worthyofinvestigation. Itisalsoimportanttoconsiderthatplantsthatdonotinducepsychiatricor
neurologicaladverseeffectsarenotnecessarilyharmless,andcouldexhibitanothertypeoftoxicity
(e.g.,cardiovascular,hepatic,andrenaltoxicity),whichwasnotthefocusofthepresentreview.
AuthorContributions: P.B.andJ.C.designedthestudy;A.F.L.F.andF.P.B.approvedthedesign. P.B.,A.F.L.F.,
A.T.andJ.C.collectedandorganizedthedataanddraftedthemanuscript. Alltheauthorscontributedtothe
revisionofthemanuscriptandapprovedthefinalcontent. Allauthorshavereadandagreedtothepublished
versionofthemanuscript.
Funding: Thisresearchreceivednoexternalfunding.
ConflictsofInterest: Theauthorsdeclarenoconflictofinterest.
References
1. Leonti,M.;Casu,L.Ethnopharmacologyoflove. Front. Pharmacol. 2018,9,567. [CrossRef]
2. Giorgetti,R.;Tagliabracci,A.;Schifano,F.;Zaami,S.;Marinelli,E.;Busardò,F.P.When“Chems”MeetSex:
ARisingPhenomenonCalled“ChemSex.”. Curr. Neuropharmacol. 2017,15,762–770. [CrossRef]
3. Pyke,R.E.SexualPerformanceAnxiety. Sex. Med. Rev. 2020,8,183–190. [CrossRef][PubMed]
4. Boivin, J.; Bunting, L.; Collins, J.A.; Nygren, K.G. International estimates on infertility prevalence and
treatment seeking: Potential need and demand for medical care. Hum. Reprod. 2007, 22, 1506–1512.
[CrossRef][PubMed]
5. Smith,J.F.;Eisenberg,M.L.;Millstein,S.G.;Nachtigall,R.D.;Shindel,A.W.;Wing,H.;Cedars,M.;Pasch,L.;
Katz,P.P.Theuseofcomplementaryandalternativefertilitytreatmentincouplesseekingfertilitycare:
DatafromaprospectivecohortintheUnitedStates. Fertil. Steril. 2010,93,2169–2174. [CrossRef][PubMed]
6. Corazza, O.; Martinotti, G.; Santacroce, R.; Chillemi, E.; Di Giannantonio, M.; Schifano, F.; Cellek, S.
Sexualenhancementproductsforsaleonline: Raisingawarenessofthepsychoactiveeffectsofyohimbine,
maca,hornygoatweed,andginkgobiloba. BioMedRes. Int. 2014,2014,1–13. [CrossRef]
7. Rao,N.;Spiller,H.A.;Hodges,N.L.;Chounthirath,T.;Casavant,M.J.;Kamboj,A.K.;Smith,G.A.AnIncrease
inDietarySupplementExposuresReportedtoUSPoisonControlCenters. J.Med. Toxicol. 2017,13,227–237.
[CrossRef][PubMed]
8. Sandroni, P. Aphrodisiacs past and present: A historical review. Clin. Auton. Res. 2001, 11, 303–307.
[CrossRef][PubMed]

## Page 38

Pharmaceuticals2020,13,309 38of51
9. Guarraci,F.A.;Bolton,J.L.“Sexystimulants”: Theinteractionbetweenpsychomotorstimulantsandsexual
behaviorinthefemalebrain. Pharmacol. Biochem. Behav. 2014,121,53–61. [CrossRef]
10. Rot,M.A.H.;Mathew,S.J.;Charney,D.S.Neurobiologicalmechanismsinmajordepressivedisorder.Can.Med.
Assoc. J.2009,180,305–313. [CrossRef]
11. Kato,T.Currentunderstandingofbipolardisorder: Towardintegrationofbiologicalbasisandtreatment
strategies. PsychiatryClin. Neurosci. 2019,73,526–540. [CrossRef][PubMed]
12. Martel,J.C.;McArthur,S.G.DopamineReceptorSubtypes,PhysiologyandPharmacology: NewLigands
andConceptsinSchizophrenia. Front. Pharmacol. 2020,11,1003. [CrossRef][PubMed]
13. Hirao,K.;Pontone,G.M.;Smith,G.S.MolecularimagingofneuropsychiatricsymptomsinAlzheimer’sand
Parkinson’sdisease. Neurosci. Biobehav. Rev. 2015,49,157–170. [CrossRef][PubMed]
14. Srivatsav,A.;Balasubramanian,A.;Pathak,U.I.;Rivera-Mirabal,J.;Thirumavalavan,N.;Hotaling,J.M.;
Lipshultz,L.I.;Pastuszak,A.W.EfficacyandSafetyofCommonIngredientsinAphrodisiacsUsedforErectile
Dysfunction: AReview. Sex. Med. Rev. 2020,8,431–442. [CrossRef][PubMed]
15. Deahl,M.Betelnut-inducedextrapyramidalsyndrome: Anunusualdruginteraction. Mov. Disord. 1989,
4,330–332. [CrossRef][PubMed]
16. Winstock,A.R.;Trivedy,C.R.;Warnakulasuriya,S.;Peters,T.J.Adependencysyndromerelatedtoarecanut
use: SomemedicalandpsychologicalaspectsamongarecanutusersintheGujaratcommunityintheUK.
Addict. Biol. 2000,5,173–179. [CrossRef][PubMed]
17. Hafeman,D.;Ahsan,H.;Islam,T.;Louis,E.Betelquid: Itstremor-producingeffectsinresidentsofAraihazar,
Bangladesh. Mov. Disord. 2005,21,567–571. [CrossRef][PubMed]
18. Senn,M.;Baiwog,F.;Winmai,J.;Mueller,I.;Rogerson,S.;Senn,N.Betelnutchewingduringpregnancy,
Madangprovince,PapuaNewGuinea. DrugAlcoholDepend. 2009,105,126–131. [CrossRef][PubMed]
19. Bhat, S.J.S.; Blank, M.D.; Balster, R.L.; Nichter, M.; Nichter, M. Areca nut dependence among chewers
inaSouthIndiancommunitywhodonotalsousetobacco. Addiction2010,105,1303–1310. [CrossRef]
20. Mirza,S.S.;Shafique,K.;Vart,P.;Arain,M.I.Arecanutchewinganddependencysyndrome:Isthedependence
comparabletosmoking? Acrosssectionalstudy. Subst. Abus. Treat. Prev. Policy2011,6,23. [CrossRef]
21. Lee,C.H.;Chiang,S.L.;Ko,A.M.-S.;Hua,C.H.;Tsai,M.H.;Warnakulasuriya,S.;Ibrahim,S.O.;Sunarjo;
Zain, R.B.; Ling, T.Y.; et al. Betel-quid dependence domains and syndrome associated with betel-quid
ingredientsamongchewers: AnAsianmulti-countryevidence. Addiction2014,109,1194–1204. [CrossRef]
[PubMed]
22. Lin,C.C.;Tamí-Maury,I.M.;Ma,W.F.;Lam,C.;Tsai,M.H.;Lin,M.T.;Li,C.I.;Liu,C.S.;Li,T.C.;Chiu,C.F.;etal.
SocialandCulturalContextofBetelQuidConsumptioninTaiwanandImplicationsforPreventionand
CessationInterventions. Subst. UseMisuse2017,52,646–655. [CrossRef]
23. Mateen, F.J.; Carone, M.; Tshering, L.; Dorji, C.; Dema, U.; Grundy, S.J.; Pokhrel, D.R.; Nirola, D.K.
Arecacatechu(palmtree)nutchewingandseizures: Anobservationalstudy. EpilepsyBehav. 2017,74,76–80.
[CrossRef]
24. Osborne,P.G.;Ko,Y.C.;Wu,M.T.;Lee,C.H.IntoxicationandsubstanceusedisordertoArecacatechunut
containing betel quid: A review of epidemiological evidence, pharmacological basis and social factors
influencingquittingstrategies. DrugAlcoholDepend. 2017,179,187–197. [CrossRef][PubMed]
25. Papke,R.L.; Bhattacharyya,I.; Hatsukami,D.K.; Moe,I.; Glatman,S.BetelNnut(areca)andSmokeless
TobaccoUseinMyanmar. Subst. UseMisuse2020,55,1385–1394. [CrossRef][PubMed]
26. Tsai,M.H.;Li,T.C.;Li,C.I.;Gritz,E.R.;Lam,C.;Chiu,C.F.;Liu,C.S.;Lai,C.C.;Hsu,W.Y.;Tamí-Maury,I.;etal.
DevelopmentandpreliminaryvalidationofamandarinChineselanguagequestionnairemeasuringbetel
quiddependencyamongadultsinTaiwan. PsychiatryRes. 2019,271,153–160. [CrossRef][PubMed]
27. Sitaram,N.; Nurnberger,J.I.; Gershon,E.S.; Gillin,J.C.CholinergicregulationofmoodandREMsleep:
Potentialmodelandmarkerofvulnerabilitytoaffectivedisorder. Am. J.Psychiatry1982, 139, 571–576.
[CrossRef]
28. Nurnberger,J.I.;Jimerson,D.C.;Simmons-Alling,S.;Tamminga,C.;Nadi,N.S.;Lawrence,D.;Sitaram,N.;
Gillin,J.C.;Gershon,E.S.Behavioral,physiological,andneuroendocrineresponsestoarecolineinnormal
twinsand“wellstate”bipolarpatients. PsychiatryRes. 1983,9,191–200. [CrossRef]
29. Dubé,S.; Kumar,N.; Ettedgui,E.; Pohl,R.; Jones,D.; Sitaram,N.CholinergicREMinductionresponse:
Separationofanxietyanddepression. Biol. Psychiatry1985,20,408–418. [CrossRef]

## Page 39

Pharmaceuticals2020,13,309 39of51
30. Overstreet,D.H.Selectivebreedingforincreasedcholinergicfunction: Developmentofanewanimalmodel
ofdepression. Biol. Psychiatry1986,21,49–58. [CrossRef]
31. Tariot,P.N.;Cohen,R.M.;Welkowitz,J.A.;Sunderland,T.;Newhouse,P.A.;Murphy,D.L.;Weingartner,H.
Multiple-Dose Arecoline Infusions in Alzheimer’s Disease. Arch. Gen. Psychiatry 1988, 45, 901–905.
[CrossRef]
32. Wager,S.;Robinson,D.;Goetz,R.;Nunes,E.;Gully,R.;Quitkin,F.CholinergicREMsleepinductionin
atypicaldepression. Biol. Psychiatry1990,27,441–446. [CrossRef][PubMed]
33. Polinsky,R.J.;Brown,R.T.;Curras,M.T.;Baser,S.M.;Baucom,C.E.;Hooper,D.R.;Marini,A.M.Central
andperipheraleffectsofarecolineinpatientswithautonomicfailure. J.Neurol. Neurosurg. Psychiatry1991,
54,807–812. [CrossRef]
34. Gillin,J.C.;Sutton,L.;Ruiz,C.;Kelsoe,J.;Dupont,R.M.;Darko,D.;Risch,S.C.;Golshan,S.;Janowsky,D.
TheCholinergicRapidEyeMovementInductionTestWithArecolineinDepression. Arch. Gen. Psychiatry
1991,48,264–270. [CrossRef][PubMed]
35. Dahl,R.E.;Ryan,N.D.;Perel,J.;Birmaher,B.;Al-Shabbout,M.;Nelson,B.;Puig-Antich,J.CholinergicREM
inductiontestwitharecolineindepressedchildren. PsychiatryRes. 1994,51,269–282. [CrossRef]
36. Molinengo,L.;Orsetti,M.;Pastorello,B.;Scordo,I.;Ghi,P.Theactionofarecolineonretrievalandmemory
storageevaluatedinthestaircasemaze. Neurobiol. Learn. Mem. 1995,63,167–173. [CrossRef][PubMed]
37. Chau,D.T.;Rada,P.;Kosloff,R.A.;Taylor,J.L.;Hoebel,B.G.Nucleusaccumbensmuscarinicreceptorsinthe
controlofbehavioraldepression: Antidepressant-likeeffectsoflocalm1antagonistintheporsoltswimtest.
Neuroscience2001,104,791–798. [CrossRef][PubMed]
38. Carvalho-Freitas, M.I.R.; Costa, M. Anxiolytic and sedative effects of extracts and essential oil from
CitrusaurantiumL.Biol. Pharm. Bull. 2002,25,1629–1633. [CrossRef][PubMed]
39. Kamalifard,M.;Farshbaf-Khalili,A.;Namadian,M.;Ranjbar,Y.;Herizchi,S.ComparisonoftheEffectof
LavenderandBitterOrangeonSleepQualityinPostmenopausalWomen: ATriple-Blind,Randomized,
ControlledClinicalTrial. WomenHealth2018,58,851–865. [CrossRef]
40. Farshbaf-Khalili, A.; Kamalifard, M.; Namadian, M. Comparison of the Effect of Lavender and Bitter
OrangeonAnxietyinPostmenopausalWomen: ATriple-Blind, Randomized, ControlledClinicalTrial.
Complement.Ther. Clin. Pract. 2018,31,132–138. [CrossRef]
41. Heydari,N.;Abootalebi,M.;Tayebi,N.;Hassanzadeh,F.;Kasraeian,M.;Emamghoreishi,M.;Akbarzadeh,M.
The Effect of Aromatherapy on Mental, Physical Symptoms, and Social Functions of Females With
Premenstrual Syndrome: A Randomized Clinical Trial. J. Fam. Med. Prim. Care 2019, 8, 2990–2996.
[CrossRef]
42. Assanangkornchai,S.;Muekthong,A.;Sam-Angsri,N.;Pattanasattayawong,U.TheuseofMitragynine
speciosa(“Krathom”),anaddictiveplant,inThailand. Subst. UseMisuse2007,42,2145–2157. [CrossRef]
[PubMed]
43. Boyer,E.W.;Babu,K.M.;Adkins,J.E.;Mccurdy,C.R.;Halpern,J.H.Self-treatmentofopioidwithdrawalusing
kratom(Mitragyniaspeciosakorth). Addiction2008,103,1048–1050. [CrossRef][PubMed]
44. Nelsen,J.L.;Lapoint,J.;Hodgman,M.J.;Aldous,K.M.SeizureandComaFollowingKratom(Mitragynina
speciosaKorth)Exposure. J.Med. Toxicol. 2010,6,424–426. [CrossRef]
45. Vicknasingam,B.;Narayanan,S.;Beng,G.T.;Mansor,S.M.Theinformaluseofketum(Mitragynaspeciosa)
foropioidwithdrawalinthenorthernstatesofpeninsularMalaysiaandimplicationsfordrugsubstitution
therapy. Int. J.DrugPolicy2010,21,283–288. [CrossRef]
46. McWhirter, L.; Morris, S. A case report of inpatient detoxification after kratom (Mitragyna speciosa)
dependence. Eur. Addict. Res. 2010,16,229–231. [CrossRef][PubMed]
47. Ahmad,K.;Aziz,Z.MitragynaspeciosauseinthenorthernstatesofMalaysia: Across-sectionalstudy.
J.Ethnopharmacol. 2012,141,446–450. [CrossRef]
48. Trakulsrichai,S.;Tongpo,A.;Sriapha,C.;Wongvisawakorn,S.;Rittilert,P.;Kaojarern,S.;Wananukul,W.
KratomAbuseinRamathibodiPoisonCenter,Thailand: AFive-Year. J.Psychoact. Drugs2012,45,404–408.
[CrossRef]
49. Forrester, M.B. Kratom exposures reported to Texas poison centers. J. Addict. Dis. 2013, 32, 396–400.
[CrossRef][PubMed]

## Page 40

Pharmaceuticals2020,13,309 40of51
50. Saingam,D.;Assanangkornchai,S.;Geater,A.F.;Balthip,Q.Patternandconsequencesofkrathom(Mitragyna
speciosaKorth.) useamongmalevillagersinsouthernThailand: Aqualitativestudy. Int. J.DrugPolicy2013,
24,351–358. [CrossRef]
51. Singh,D.;Müller,C.P.;Vicknasingam,B.K.Kratom(Mitragynaspeciosa)dependence,withdrawalsymptoms
andcravinginregularusers. DrugAlcoholDepend. 2014,139,132–137. [CrossRef][PubMed]
52. Swogger,M.T.;Hart,E.;Erowid,F.;Erowid,E.;Trabold,N.;Yee,K.;Parkhurst,K.A.;Priddy,B.M.;Walsh,Z.
ExperiencesofKratomUsers: AQualitativeAnalysis. J.Psychoact. Drugs2015,47,360–367. [CrossRef]
53. Anwar,M.;Law,R.;Schier,J.NotesfromtheField: Kratom(Mitragynaspeciosa)ExposuresReportedto
PoisonCenters—UnitedStates,2010–2015. MMWR.Morb. Mortal. Wkly. Rep. 2016,65,748–749. [CrossRef]
[PubMed]
54. Saingam,D.;Assanangkornchai,S.;Geater,A.F.;Lerkiatbundit,S.Factoranalyticalinvestigationofkrathom
(mitragynaspeciosakorth.)withdrawalsyndromeinThailand.J.Psychoact.Drugs2016,48,76–85.[CrossRef]
55. Buresh,M.Treatmentofkratomdependencewithbuprenorphine-naloxonemaintenance. J.Addict. Med.
2018,12,481–483. [CrossRef][PubMed]
56. Singh, D.; Narayanan, S.; Müller, C.P.; Swogger, M.T.; Rahim, A.A.; Leong Bin Abdullah, M.F.I.;
Vicknasingam,B.K.;Marc,T.S.SeverityofKratom(MitragynaspeciosaKorth.) PsychologicalWithdrawal
Symptoms. J.Psychoact. Drugs2018,50,445–450. [CrossRef]
57. Mackay, L.; Abrahams, R. Novel case of maternal and neonatal kratom dependence and withdrawal.
Can.Fam.Physician2018,64,121–122. [PubMed]
58. Murthy, P.; Clark, D. An unusual cause for neonatal abstinence syndrome. Paediatr. Child Health 2019,
24,12–14. [CrossRef]
59. Diep,J.;Chin,D.T.;Gupta,S.;Syed,F.;Xiong,M.;Cheng,J.Kratom,anEmergingDrugofAbuse: ACase
ReportofOverdoseandManagementofWithdrawal. AAPract. 2018,10,192–194. [CrossRef]
60. Tatum,W.O.;Hasan,T.F.;Coonan,E.E.;Smelick,C.P.Recurrentseizuresfromchronickratomuse,anatypical
herbalopioid. EpilepsyBehav. CaseRep. 2018,10,18–20. [CrossRef][PubMed]
61. Khazaeli,A.;Jerry,J.M.;Vazirian,M.TreatmentofKratomWithdrawalandAddictionWithBuprenorphine.
J.Addict. Med. 2018,12,493–495. [CrossRef][PubMed]
62. Singh,D.;Narayanan,S.;Müller,C.P.;Vicknasingam,B.;Yücel,M.;Ho,E.T.W.;Hassan,Z.;Mansor,S.M.
Long-TermCognitiveEffectsofKratom(MitragynaspeciosaKorth.) Use. J.Psychoact. Drugs2019,51,19–27.
[CrossRef]
63. Abdullah,M.F.I.;Singh,D.;Swogger,M.T.;Rahim,A.A.;Vicknasingam,B.Theprevalenceofpsychotic
symptomsinkratom(MitragynaspeciosaKorth.) UsersinMalaysia. AsianJ.Psychiatr. 2019,43,197–201.
[CrossRef]
64. Eggleston,W.;Stoppacher,R.;Suen,K.;Marraffa,J.M.;Nelson,L.S.KratomUseandToxicitiesintheUnited
States. Pharmacotherapy2019,39,775–777. [CrossRef][PubMed]
65. Meireles,V.;Rosado,T.;Barroso,M.;Soares,S.;Gonçalves,J.;Luís,Â.;Caramelo,D.;Simão,A.;Fernández,N.;
Duarte, A.; et al. Mitragyna speciosa: Clinical, Toxicological Aspects and Analysis in Biological and
Non-BiologicalSamples. Medicines2019,6,35. [CrossRef][PubMed]
66. Saref,A.;Suraya,S.;Singh,D.;Grundmann,O.;Narayanan,S.;Swogger,M.T.;Prozialeck,W.C.;Boyer,E.;
Chear,N.J.Y.;Balasingam,V.Self-reportedprevalenceandseverityofopioidandkratom(Mitragynaspeciosa
korth.) sideeffects. J.Ethnopharmacol. 2019,238,111876. [CrossRef][PubMed]
67. Stanciu,C.N.;Gnanasegaram,S.A.;Ahmed,S.;Penders,T.KratomWithdrawal: ASystematicReviewwith
CaseSeries. J.Psychoact. Drugs2019,51,12–18. [CrossRef][PubMed]
68. Schmuhl,K.K.;Gardner,S.M.;Cottrill,C.B.;Bonny,A.E.Homeinductionandoutpatienttreatmentofkratom
usedisorderwithbuprenorphine-naloxone: Acasereportinayoungadult. Subst. Abus. 2020,41,311–314.
[CrossRef]
69. Afzal,H.;Esang,M.;Rahman,S.ACaseofKratom-inducedSeizures. Cureus2020,12,e6588. [CrossRef]
70. Garcia-Romeu, A.; Cox, D.J.; Smith, K.E.; Dunn, K.E.; Griffiths, R.R. Kratom (Mitragyna speciosa):
Userdemographics,usepatterns,andimplicationsfortheopioidepidemic. DrugAlcoholDepend. 2020,
208,107849. [CrossRef]
71. Singh,D.;Narayanan,S.;Suraya,S.;Saref,A.;Grundmann,O.;Prozialeck,W.C.;Corazza,O.;Swogger,M.T.;
Griffin, O.; Balasingam, V. Public Perceptions toward Kratom (Mitragyna Speciosa) Use in Malaysia.
J.Psychoact.Drugs2020,52,282–288. [CrossRef][PubMed]

## Page 41

Pharmaceuticals2020,13,309 41of51
72. Apryani,E.;Hidayat,M.T.;Moklas,M.A.A.;Fakurazi,S.;Idayu,N.F.EffectsofmitragyninefromMitragyna
speciosaKorthleavesonworkingmemory. J.Ethnopharmacol. 2010,129,357–360. [CrossRef][PubMed]
73. Karinen,R.;Fosen,J.T.;Rogde,S.;Vindenes,V.Anaccidentalpoisoningwithmitragynine. ForensicSci. Int.
2014,245,e29–e32. [CrossRef][PubMed]
74. Yusoff,N.H.M.;Suhaimi,F.W.;Vadivelu,R.K.;Hassan,Z.;Rümler,A.;Rotter,A.;Amato,D.;Dringenberg,H.C.;
Mansor,S.M.;Navaratnam,V.;etal. Abusepotentialandadversecognitiveeffectsofmitragynine(kratom).
Addict. Biol. 2016,21,98–110. [CrossRef]
75. Hemby,S.E.; Mcintosh,S.; Leon,F.; Cutler,S.J.; Mccurdy,C.R.Abuseliabilityandtherapeuticpotential
oftheMitragynaspeciosa(kratom)alkaloidsmitragynineand7-hydroxymitragynine. Addict. Biol. 2019,
24,874–885. [CrossRef][PubMed]
76. Hassan, Z.; Suhaimi, F.W.; Ramanathan, S.; Ling, K.H.; Effendy, M.A.; Müller, C.P.; Dringenberg, H.C.
Mitragynine (Kratom) impairs spatial learning and hippocampal synaptic transmission in rats.
J.Psychopharmacol. 2019,33,908–918. [CrossRef]
77. Vadnal,R.;Parthasarathy,L.;Parthasarathy,R.TheUseofGinsengasanAdjunctinTreatment-Resistant
Depression. Nutr. Neurosci. 1998,1,83–85. [CrossRef]
78. Joshi, K.G.; Faubion, M.D. Mania and Psychosis Associated with St. John’s Wort and Ginseng.
Psychiatry(Edgmont)2005,2,56–61.
79. Kennedy,D.O.;Scholey,A.B.;Wesnes,K.A.Dosedependentchangesincognitiveperformanceandmood
followingacuteadministrationofGinsengtohealthyyoungvolunteers. Nutr. Neurosci. 2001,4,295–310.
[CrossRef]
80. Kennedy,D.O.;Scholey,A.B.;Wesnes,K.A.Differential,dosedependentchangesincognitiveperformance
followingacuteadministrationofaGinkgobiloba/Panaxginsengcombinationtohealthyyoungvolunteers.
Nutr. Neurosci. 2001,4,399–412. [CrossRef][PubMed]
81. Vázquez,I.;Agüera-Ortiz,L.F.Herbalproductsandserioussideeffects: Acaseofginseng-inducedmanic
episode. ActaPsychiatr. Scand. 2002,105,76–77. [PubMed]
82. Hartley,D.E.;Elsabagh,S.;File,S.E.Gincosan(Acombinationofginkgobilobaandpanaxginseng):Theeffects
onmoodandcognitionof6and12weeks’treatmentinpost-menopausalwomen. Nutr. Neurosci. 2004,
7,325–333. [CrossRef][PubMed]
83. Niederhofer,H.Panaxginsengmayimprovesomesymptomsofattention-deficithyperactivitydisorder.
J.Diet.Suppl. 2009,6,22–27. [CrossRef][PubMed]
84. Jeong,H.G.; Ko,Y.H.;Oh,S.Y.;Han,C.; Kim,T.; Joe,S.H.EffectofKoreanRedGinsengasanadjuvant
treatmentforwomenwithresidualsymptomsofmajordepression. AsiaPac. Psychiatry2015,7,330–336.
[CrossRef][PubMed]
85. Norelli,L.J.;Xu,C.ManicpsychosisassociatedwithGinseng: Areportoftwocasesanddiscussionofthe
literature. J.Diet. Suppl. 2015,12,119–125. [CrossRef][PubMed]
86. Yennurajalingam, S.; Reddy, A.; Tannir, N.M.; Chisholm, G.B.; Lee, R.T.; Lopez, G.; Escalante, C.P.;
Manzullo,E.F.;Hume,S.F.;Williams,J.L.;etal.High-DoseAsianGinseng(PanaxGinseng)forCancer-Related
Fatigue: APreliminaryReport. Integr. CancerTher. 2015,14,419–427. [CrossRef]
87. Yadav,P.;Stigall,K.;Johnson,H.E.;Rayapati,A.O.;Chopra,N.Functionalfoods: Howfunctionalarethey?
Acasereportofsupplement-inducedpsychosis. Int. J.PsychiatryMed. 2016,51,479–485. [CrossRef]
88. Bostock,E.;Kirkby,K.;Garry,M.;Taylor,B.;Hawrelak,J.A.Maniaassociatedwithherbalmedicines,other
thancannabis: Asystematicreviewandqualityassessmentofcasereports. Front. Psychiatry2018,9,208.
[CrossRef][PubMed]
89. Farnia,V.;Alikhani,M.;Ebrahimi,A.;Golshani,S.;Bahmani,D.S.;Brand,S.Ginsengtreatmentimproves
thesexualsideeffectsofmethadonemaintenancetreatment. PsychiatryRes. 2019,276,142–150. [CrossRef]
[PubMed]
90. Görgülü,S.ManicEpisodeAssociatedwithGinseng: ACaseReport. Int. J.Med. Rev. CaseRep. 2020,
4,111–113. [CrossRef]
91. Lee,J.;Lee,A.;Kim,J.-H.;Shin,Y.M.;Kim,S.-J.;Cho,W.D.;Lee,S.I.Effectofomega-3andKoreanredginseng
onchildrenwithattentiondeficithyperactivitydisorder: Anopen-labelpilotstudy. Clin. Psychopharmacol.
Neurosci. 2020,18,75–80. [CrossRef][PubMed]

## Page 42

Pharmaceuticals2020,13,309 42of51
92. Jones,B.D.;Runikis,A.M.Interactionofginsengwithphenelzine. J.Clin. Psychopharmacol. 1987,7,201–202.
[CrossRef][PubMed]
93. Lyon, M.R.; Cline, J.C.; De Zepetnek, J.T.; Shan, J.J.; Pang, P.; Benishin, C. Effect of the herbal extract
combinationPanaxquinquefoliumandGinkgobilobaonattention-deficithyperactivitydisorder: Apilot
study. J.PsychiatryNeurosci. 2001,26,221–228. [PubMed]
94. Ma, H.; Sullivan-Halley, J.; Smith, A.W.; Neuhouser, M.L.; Alfano, C.M.; Meeske, K.; George, S.M.;
McTiernan,A.;McKean-Cowdin,R.;Baumgartner,K.B.;etal.Estrogenicbotanicalsupplements,health-related
qualityoflife,fatigue,andhormone-relatedsymptomsinbreastcancersurvivors: AHEALstudyreport.
BMCComplement. Altern. Med. 2011,11,109. [CrossRef]
95. Papeschi,R.;Sourkers,T.L.;Youdim,M.B.Theeffectofyohimbineonbrainserotoninmetabolism,motor
behaviorandbodytemperatureoftherat. Eur. J.Pharmacol. 1971,15,318–326. [CrossRef]
96. MacKintosh,C.G.;VanReenen,G.Comparisonofyohimbine,4-aminopyridineanddoxapramantagonism
ofxylazinesedationindeer(Cervuselaphus). N.Z.Vet. J.1984,32,181–184. [CrossRef][PubMed]
97. Price,L.H.;Charney,D.S.;Heninger,G.R.Threecasesofmanicsymptomsfollowingyohimbineadministration.
Am. J.Psychiatry1984,141,1267–1268. [CrossRef]
98. Charney,D.S.;Heninger,G.R.;Breier,A.NoradrenergicFunctioninPanicAnxiety. Arch. Gen. Psychiatry
1984,41,751–763. [CrossRef]
99. Linden,C.H.;Vellman,W.P.;Rumack,B.Yohimbine:Anewstreetdrug.Ann.Emerg.Med.1985,14,1002–1004.
[CrossRef]
100. Charney, S.; Woods, S.W.; Goodman, K.; Heninger, R. Neurobiological Mechanisms of Panic Anxiety:
Biochemical and Behavioral Correlates of Yohimbine-Induced Panic Attacks. Am. J. Psychiatry 1987,
144,1030–1036. [CrossRef]
101. Johnston,A.L.;Baldwin,H.A.;File,S.E.Measuresofanxietyandstressintheratfollowingchronictreatment
withyohimbine. J.Psychopharmacol. 1988,2,33–38. [CrossRef][PubMed]
102. Heninger,G.R.;Charney,D.S.;Price,L.H.alpha2-Adrenergicreceptorsensitivityindepression. Theplasma
MHPG,behavioral,andcardiovascularresponsestoyohimbine. Arch. Gen. Psychiatry1988,45,718–726.
[CrossRef][PubMed]
103. Dilsaver, S.C.; Davidson, R.K. Chronic treatment with amitriptyline produces subsensitivity to the
hypothermic effects of yohimbine. Prog. Neuro-Psychopharmacology Biol. Psychiatry 1989, 13, 211–215.
[CrossRef]
104. Rosenblum,L.A.;Coplan,J.D.;Friedman,S.;Bassoff,T.Dose-responseeffectsoforalyohimbineinunrestrained
primates. Biol. Psychiatry1991,29,647–657. [CrossRef]
105. Charney,D.S.;Woods,S.W.;Krystal,J.H.;Nagy,L.M.;Heninger,G.R.Noradrenergicneuronaldysregulation
in panic disorder: The effects of intravenous yohimbine and clonidine in panic disorder patients.
ActaPsychiatr.Scand. 1992,86,273–282. [CrossRef]
106. Friesen,K.;Palatnick,W.;Tenenbein,M.Benigncourseaftermassiveingestionofyohimbine. J.Emerg. Med.
1993,11,287–288. [CrossRef]
107. Kollias-Baker,C.A.;Court,M.H.;Williams,L.L.Influenceofyohimbineandtolazolineonthecardiovascular,
respiratory,andsedativeeffectsofxylazineinthehorse. J.Vet. Pharmacol. Ther. 1993,16,350–358. [CrossRef]
[PubMed]
108. Wooten,V.Effectivenessofyohimbineintreatingnarcolepsy. South. Med. J.1994,87,1065–1066. [CrossRef]
[PubMed]
109. Southwick,S.M.;Morgan,C.A.,III;Charney,D.S.;High,J.R.Yohimbineuseinanaturalsetting: Effectson
posttraumaticstressdisorder. Biol. Psychiatry1999,46,442–444. [CrossRef]
110. Cameron,O.G.;Zubieta,J.K.;Grunhaus,L.;Minoshima,S.Effectsofyohimbineoncerebralbloodflow,
symptoms,andphysiologicalfunctionsinhumans. Psychosom. Med. 2000,62,549–559. [CrossRef]
111. Morales,L.;Perez-Garcia,C.;Alguacil,L.F.Effectsofyohimbineontheantinociceptiveandplaceconditioning
effectsofopioidagonistsinrodents. Br. J.Pharmacol. 2001,133,172–178. [CrossRef][PubMed]
112. Matsunaga,T.;Tsukada,H.;Nishiyama,S.;Sekine,Y.;Kakiuchi,T.;Iyo,M.;Mori,N.Yohimbineincreases
thebindingpotentialfor[11C]flumazenilinthemonkeybrain. J.NeuralTransm. 2001,108,1375–1382.
[CrossRef][PubMed]

## Page 43

Pharmaceuticals2020,13,309 43of51
113. Stine,S.M.;Southwick,S.M.;Petrakis,I.L.;Kosten,T.R.;Charney,D.S.;Krystal,J.H.Yohimbine-induced
withdrawal and anxiety symptoms in opioid-dependent patients. Biol. Psychiatry 2002, 51, 642–651.
[CrossRef]
114. Shepard,J.D.;Bossert,J.M.;Liu,S.Y.;Shaham,Y.Theanxiogenicdrugyohimbinereinstatesmethamphetamine
seekinginaratmodelofdrugrelapse. Biol. Psychiatry2004,55,1082–1089. [CrossRef]
115. Lee,B.;Tiefenbacher,S.;Platt,D.M.;Spealman,R.D.Pharmacologicalblockadeofα2-adrenoceptorsinduces
reinstatementofcocaine-seekingbehaviorinsquirrelmonkeys. Neuropsychopharmacology2004,29,686–693.
[CrossRef]
116. Ehlert,U.;Erni,K.;Hebisch,G.;Nater,U.Salivaryα-amylaselevelsafteryohimbinechallengeinhealthy
men. J.Clin. Endocrinol. Metab. 2006,91,5130–5133. [CrossRef]
117. Keedy,S.K.;Connor,M.M.;Beenken,B.;Dorflinger,J.;Abel,M.;Erwin,R.J.Noradrenergicantagonismof
theP13andN40componentsoftheratauditoryevokedpotential. Psychopharmacology2007,190,117–125.
[CrossRef]
118. Giampreti,A.;Lonati,D.;Locatelli,C.;Rocchi,L.;Campailla,M.T.Acuteneurotoxicityafteryohimbine
ingestionbyabodybuilder. Clin. Toxicol. 2009,47,827–829. [CrossRef]
119. Powers,M.B.;Smits,J.A.J.;Otto,M.W.;Sanders,C.;Emmelkamp,P.M.G.Facilitationoffearextinctionin
phobicparticipantswithanovelcognitiveenhancer: Arandomizedplacebocontrolledtrialofyohimbine
augmentation. J.AnxietyDisord. 2009,23,350–356. [CrossRef]
120. Banna,K.M.;Back,S.E.;Do,P.;See,R.E.Yohimbinestresspotentiatesconditionedcue-inducedreinstatement
ofheroin-seekinginrats. Behav. BrainRes. 2010,208,144–148. [CrossRef]
121. Sommer,M.;Braumann,M.;Althoff,T.;Backhaus,J.;Kordon,A.;Junghanns,K.;Ehrenthal,D.;Bartmann,U.;
Hohagen,F.;Broocks,A.Psychologicalandneuroendocrineresponsestosocialstressandtotheadministration
ofthealpha-2-receptorantagonist,yohimbine,inhighlytrainedenduranceathletesincomparisontountrained
healthycontrols. Pharmacopsychiatry2011,44,129–134. [CrossRef][PubMed]
122. Umhau,J.C.;Schwandt,M.L.;Usala,J.;Geyer,C.;Singley,E.;George,D.T.;Heilig,M.Pharmacologically
inducedalcoholcravingintreatmentseekingalcoholicscorrelateswithalcoholismseverity,butisinsensitive
toacamprosate. Neuropsychopharmacology2011,36,1178–1186. [CrossRef][PubMed]
123. Berman,S.;Suyenobu,B.;Naliboff,B.D.;Bueller,J.;Stains,J.;Wong,H.;Mandelkern,M.;Fitzgerald,L.;
Ohning,G.;Gupta,A.;etal. Evidenceforalterationsincentralnoradrenergicsignalinginirritablebowel
syndrome. Neuroimage2012,63,1854–1863. [CrossRef]
124. Li,S.;Zou,S.;Coen,K.;Funk,D.;Shram,M.J.;Lê,A.D.Sexdifferencesinyohimbine-inducedincreasesin
thereinforcingefficacyofnicotineinadolescentrats. Addict. Biol. 2014,19,156–164. [CrossRef][PubMed]
125. Lê,A.D.;Funk,D.;Coen,K.;Li,Z.;Shaham,Y.Roleofcorticotropin-releasingfactorinthemedianraphe
nucleusinyohimbine-inducedreinstatementofalcoholseekinginrats. Addict. Biol. 2013, 18, 448–451.
[CrossRef][PubMed]
126. Anderson,C.;Anderson,D.;Harre,N.;Wade,N.Casestudy: Twofatalcasereportsofacuteyohimbine
intoxication. J.Anal. Toxicol. 2013,37,611–614. [CrossRef]
127. Stopponi,S.;DeGuglielmo,G.;Somaini,L.;Cippitelli,A.;Cannella,N.;Kallupi,M.;Ubaldi,M.;Heilig,M.;
Demopulos,G.;Gaitanaris,G.;etal.ActivationofPPARcbyPioglitazonePotentiatestheEffectsofNaltrexone
onAlcoholDrinkingandRelapseinmsPRats. Alcohol. Clin. Exp. Res. 2013,37,1351–1360. [CrossRef]
128. Moran-Santa Maria, M.M.; McRae-Clark, A.; Baker, N.L.; Ramakrishnan, V.; Brady, K.T. Yohimbine
administrationandcue-reactivityincocaine-dependentindividuals.Psychopharmacology2014,231,4157–4165.
[CrossRef]
129. Li,Q.;Lin,J.;Zhang,Y.;Liu,X.;Chen,X.Q.;Xu,M.Q.;He,L.;Li,S.;Guo,N.Differentialbehavioralresponses
ofzebrafishlarvaetoyohimbinetreatment. Psychopharmacology2015,232,197–208. [CrossRef]
130. Ball,K.T.;Jarsocrak,H.;Hyacinthe,J.;Lambert,J.;Lockowitz,J.;Schrock,J.Yohimbinereinstatesextinguished
3,4-methylenedioxymethamphetamine(MDMA;ecstasy)seekinginratswithpriorexposuretochronic
yohimbine. Behav. BrainRes. 2015,294,1–6. [CrossRef]
131. Vo,L.;Hood,S.;Drummond,P.D.InvolvementofOpioidReceptorsandα2-AdrenoceptorsinInhibitory
PainModulationProcesses: ADouble-BlindPlacebo-ControlledCrossoverStudy. J.Pain2016,17,1164–1173.
[CrossRef][PubMed]

## Page 44

Pharmaceuticals2020,13,309 44of51
132. Moran-SantaMaria,M.M.;Baker,N.L.;McRae-Clark,A.L.;Prisciandaro,J.J.;Brady,K.T.Effectsofyohimbine
anddrugcuesonimpulsivityandattentionincocaine-dependentmenandwomenandsex-matchedcontrols.
DrugAlcoholDepend. 2016,162,56–63. [CrossRef][PubMed]
133. Kluen, L.M.; Agorastos, A.; Wiedemann, K.; Schwabe, L. Noradrenergic Stimulation Impairs Memory
GeneralizationinWomen. J.Cogn. Neurosci. 2017,29,1279–1291. [CrossRef][PubMed]
134. Vo,L.;Drummond,P.D.Effectofcombinedopioidreceptorandα2-adrenoceptorblockadeonanxietyand
electricallyevokedstartleresponses. J.Psychopharmacol. 2017,31,722–729. [CrossRef]
135. Herman,A.M.;Critchley,H.D.;Duka,T.TheimpactofYohimbine-inducedarousalonfacetsofbehavioural
impulsivity. Psychopharmacology2019,236,1783–1795. [CrossRef]
136. Prescott,J.;Jamieson,D.;Emdur,N.;Duffield,P.Acuteeffectsofkavaonmeasuresofcognitiveperformance,
physiologicalfunctionandmood. DrugAlcoholRev. 1993,12,49–57. [CrossRef]
137. Wheatley, D. Stress-induced insomnia treated with kava and valerian: Singly and in combination.
Hum.Psychopharmacol. 2001,16,353–356. [CrossRef]
138. Connor,K.M.;Davidson,J.R.;Churchill,L.E.Adverse-EffectProfileofKava. CNSSpectr. 2001,6,848–853.
[CrossRef]
139. Meseguer,E.;Taboada,R.;Sánchez,V.;Mena,M.A.;Campos,V.;GarcíaDeYébenes,J.Life-threatening
parkinsonisminducedbykava-kava. Mov. Disord. 2002,17,195–196. [CrossRef]
®
140. Gastpar,M.;Klimm,H.D.Treatmentofanxiety,tensionandrestlessnessstateswithKavaspecialextractWS
1490ingeneralpractice: Arandomizedplacebo-controlleddouble-blindmulticentertrial. Phytomedicine
2003,10,631–639. [CrossRef]
141. Cairney,S.;Maruff,P.;Clough,A.R.;Collie,A.;Currie,J.;Currie,B.J.Saccadeandcognitiveimpairment
associatedwithkavaintoxication. Hum. Psychopharmacol. 2003,18,525–533. [CrossRef][PubMed]
142. Cagnacci,A.;Arangino,S.;Renzi,A.;Zanni,A.L.;Malmusi,S.;Volpe,A.Kava-Kavaadministrationreduces
anxietyinperimenopausalwomen. Maturitas2003,44,103–109. [CrossRef][PubMed]
143. Shinomiya,K.;Inoue,T.;Utsu,Y.;Tokunaga,S.;Masuoka,T.;Ohmori,A.;Kamei,C.Effectsofkava-kava
extractonthesleep-wakecycleinsleep-disturbedrats. Psychopharmacology2005,180,564–569. [CrossRef]
[PubMed]
144. Perez,J.;Holmes,J.F.AlteredmentalstatusandataxiasecondarytoacuteKavaingestion. J.Emerg. Med.
2005,28,49–51. [CrossRef][PubMed]
145. Sarris,J.;Kavanagh,D.J.;Deed,G.;Bone,K.M.St. John’swortandKavaintreatingmajordepressivedisorder
withcomorbidanxiety: Arandomiseddouble-blindplacebo-controlledpilottrial. Hum. Psychopharmacol.
2009,24,41–48. [CrossRef]
146. Sarris,J.;Stough,C.;Teschke,R.;Wahid,Z.T.;Bousman,C.A.;Murray,G.;Savage,K.M.;Mouatt,P.;Ng,C.;
Schweitzer,I.KavaforthetreatmentofgeneralizedanxietydisorderRCT:Analysisofadversereactions,
liverfunction,addiction,andsexualeffects. Phyther. Res. 2013,27,1723–1728. [CrossRef]
147. Sarris, J.; Stough, C.; Bousman, C.A.; Wahid, Z.T.; Murray, G.; Teschke, R.; Savage, K.M.; Dowell, A.;
Ng,C.;Schweitzer,I.Kavainthetreatmentofgeneralizedanxietydisorder: Adouble-blind,randomized,
placebo-controlledstudy. J.Clin. Psychopharmacol. 2013,33,643–648. [CrossRef][PubMed]
148. Malhotra,N.;Starkey,N.J.;Charlton,S.G.Drivingundertheinfluenceofdrugs: Perceptionsandattitudesof
NewZealanddrivers. Accid. Anal. Prev. 2017,106,44–52. [CrossRef]
149. Wang, D.; Yang, L.E.; Wang, J.; Hu, G.; Liu, Z.Y.; Yan, D.; Serikuly, N.; Alpyshov, E.T.; Demin, K.A.;
Galstyan, D.S.; et al. Behavioral and physiological effects of acute and chronic kava exposure in adult
zebrafish. Neurotoxicol. Teratol. 2020,79,106881. [CrossRef]
150. Fragoulis,A.;Siegl,S.;Fendt,M.;Jansen,S.;Soppa,U.;Brandenburg,L.O.;Pufe,T.;Weis,J.;Wruck,C.J.
OraladministrationofmethysticinimprovescognitivedeficitsinamousemodelofAlzheimer’sdisease.
RedoxBiol. 2017,12,843–853. [CrossRef]
151. DaSilva,A.L.;Bardini,S.;Nunes,D.S.;Elisabetsky,E.AnxiogenicpropertiesofPtychopetalumolacoides
Benth. (Marapuama). Phyther. Res. 2002,16,223–226. [CrossRef][PubMed]
152. DaSilva,A.L.;DaSilvaMartins,B.;Linck,V.D.M.;Herrmann,A.P.;Mai,N.;Nunes,D.S.;Elisabetsky,E.
MK801-andscopolamine-inducedamnesiasarereversedbyanAmazonianherballocallyusedasa“brain
tonic.”. Psychopharmacology2009,202,165–172. [CrossRef][PubMed]

## Page 45

Pharmaceuticals2020,13,309 45of51
153. Chiu,S.;Gericke,N.;Farina-Woodbury,M.;Badmaev,V.;Raheb,H.;Terpstra,K.;Antongiorgi,J.;Bureau,Y.;
Cernovsky, Z.; Hou, J.; et al. Proof-of-concept randomized controlled study of cognition effects of the
proprietaryextractsceletiumtortuosum(Zembrin)targetingphosphodiesterase-4incognitivelyhealthy
subjects: ImplicationsforAlzheimer’sdementia. Evidence-BasedComplement. Altern. Med. 2014,2014,682014.
[CrossRef]
154. Huang,Y.J.;Jiann,B.P.AssociationofArecaNutChewingWithRiskofErectileDysfunction. Sex. Med. 2017,
5,e163–e168. [CrossRef][PubMed]
155. Bales, A.; Peterson, M.J.; Ojha, S.; Upadhaya, K.; Adhikari, B.; Barrett, B. Associations between betel
nut (Areca catechu) and symptoms of schizophrenia among patients in Nepal: A longitudinal study.
PsychiatryRes. 2009,169,203–211. [CrossRef][PubMed]
156. Chu, N.S. Neurological aspects of areca and betel chewing. Addict. Biol. 2002, 7, 111–114. [CrossRef]
[PubMed]
157. LoFaro,A.F.;DiTrana,A.;LaMaida,N.;Tagliabracci,A.;Giorgetti,R.;Busardò,F.P.Biomedicalanalysisof
NewPsychoactiveSubstances(NPS)ofnaturalorigin. J.Pharm. Biomed. Anal. 2020,179,112945. [CrossRef]
158. Norton,S.A.Betel: Consumptionandconsequences. J.Am. Acad. Dermatol. 1998,38,81–88. [CrossRef]
[PubMed]
159. Gupta,P.C.; Warnakulasuriya,S.Globalepidemiologyofarecanutusage. Addict. Biol. 2002, 7, 77–83.
[CrossRef]
160. Agostini-Costa,T.daS.Bioactivecompoundsandhealthbenefitsofsomepalmspeciestraditionallyusedin
AfricaandtheAmericas—Areview. J.Ethnopharmacol. 2018,224,202–229. [CrossRef]
161. Srimany,A.;George,C.;Naik,H.R.;Pinto,D.G.;Chandrakumar,N.;Pradeep,T.Developmentalpatterning
andsegregationofalkaloidsinarecanut(seedofArecacatechu)revealedbymagneticresonanceandmass
spectrometryimaging. Phytochemistry2016,125,35–42. [CrossRef][PubMed]
162. Peng,W.;Liu,Y.J.;Wu,N.;Sun,T.;He,X.Y.;Gao,Y.X.;Wu,C.J.ArecacatechuL.(Arecaceae): Areviewofits
traditionaluses,botany,phytochemistry,pharmacologyandtoxicology. J.Ethnopharmacol. 2015,164,340–356.
[CrossRef]
163. Liu,Y.J.;Peng,W.;Hu,M.B.;Xu,M.;Wu,C.J.Thepharmacology,toxicologyandpotentialapplicationsof
arecoline: Areview. Pharm. Biol. 2016,54,2753–2760. [CrossRef][PubMed]
164. Gheddar,L.;Ricaut,F.X.;Ameline,A.;Brucato,N.;Tsang,R.;Leavesley,M.;Raul,J.S.;Kintz,P.Testingfor
BetelNutAlkaloidsinHairofPapuansAbusersusingUPLC-MS/MSandUPLC-Q-Tof-MS.J.Anal. Toxicol.
2020,44,41–48. [CrossRef][PubMed]
165. Gupta,A.K.; Tulsyan,S.; Thakur,N.; Sharma,V.; Sinha,D.N.; Mehrotra,R.Chemistry,metabolismand
pharmacology of carcinogenic alkaloids present in areca nut and factors affecting their concentration.
Regul.Toxicol.Pharmacol. 2020,110,104548. [CrossRef][PubMed]
166. Salehi,B.;Konovalov,D.A.;Fru,P.;Kapewangolo,P.;Peron,G.;Ksenija,M.S.;Cardoso,S.M.;Pereira,O.R.;
Nigam,M.;Nicola,S.;etal. Arecacatechu—Fromfarmtofoodandbiomedicalapplications. Phyther. Res.
2020,34,2140–2158. [CrossRef]
167. Horenstein,N.A.;Quadri,M.;Stokes,C.;Shoaib,M.;Papke,R.L.Crackingthebetelnut: Cholinergicactivity
ofarecaalkaloidsandrelatedcompounds. NicotineTob. Res. 2019,21,805–812. [CrossRef]
168. Thiele,A.MuscarinicSignalingintheBrain. Annu. Rev. Neurosci. 2013,36,271–294. [CrossRef]
169. Coppola, M.; Mondola, R. Potential action of betel alkaloids on positive and negative symptoms of
schizophrenia: Areview. Nord. J.Psychiatry2012,66,73–78. [CrossRef]
170. Meltzer,L.T.;Rosecrans,J.A.Discriminativestimuluspropertiesofarecoline: Anewapproachforstudying
centralmuscarinicreceptors. Psychopharmacology1981,75,383–387. [CrossRef]
171. Avery,E.E.;Baker,L.D.;Asthana,S.PotentialRoleofMuscarinicAgonistsinAlzheimer’sDisease.DrugsAging
1997,11,450–459. [CrossRef][PubMed]
172. Chandradasa,M.;Rathnayake,L.Socio-culturalandneurobiologicalperspectivesofbetelnutchewingin
schizophrenia. AsianJ.Psychiatr. 2018,37,38–39. [CrossRef][PubMed]
173. Kuruppuarachchi,K.;Williams,S.Beteluseandschizophrenia. Br. J.Psychiatry2003,182,455. [CrossRef]
174. Sullivan, R.J.; Andres, S.; Otto, C.; Miles, W.; Kydd, R. The Effects of an Indigenous Muscarinic Drug,
BetelNut(Arecacatechu),ontheSymptomsofSchizophrenia: ALongitudinalStudyinPalau,Micronesia.
Am.J.Psychiatry2007,164,670–673. [CrossRef][PubMed]

## Page 46

Pharmaceuticals2020,13,309 46of51
175. Moran,S.P.;Maksymetz,J.;Conn,P.J.TargetingMuscarinicAcetylcholineReceptorsfortheTreatmentof
PsychiatricandNeurologicalDisorders. TrendsPharmacol. Sci. 2019,40,1006–1020. [CrossRef][PubMed]
176. Chu,N.S.EffectsofBetelchewingonthecentralandautonomicnervoussystems. J.Biomed. Sci. 2001,
8,229–236. [CrossRef]
177. Molinengo,L.;Cassone,M.C.;Orsetti,M.Actionofarecolineonthelevelsofacetylcholine,norepinephrine
and dopamine in the mouse central nervous system. Pharmacol. Biochem. Behav. 1986, 24, 1801–1803.
[CrossRef]
178. Manzanares,J.;Julian,M.;Carrascosa,A.RoleoftheCannabinoidSysteminPainControlandTherapeutic
ImplicationsfortheManagementofAcuteandChronicPainEpisodes.Curr.Neuropharmacol.2006,4,239–257.
[CrossRef]
179. Garg,A.; Chaturvedi,P.; Gupta,P.C.Areviewofthesystemicadverseeffectsofarecanutorbetelnut.
IndianJ.Med. Paediatr. Oncol. 2014,35,3–9. [CrossRef]
180. Boucher,B.J.;Mannan,N.MetaboliceffectsoftheconsumptionofArecacatechu.Addict.Biol.2002,7,103–110.
[CrossRef]
181. Johnston, G.; Krogsgaard-Larsen, P.; Stephanson, A. Betel nut constituents as inhibitors of
gamma-aminobutyricaciduptake. Nature1975,258,627–628. [CrossRef][PubMed]
182. Lodge,D.;Johnston,G.A.R.;Curtis,D.R.;Brand,S.J.EffectsoftheArecanutconstituentsarecaidineand
guvacineontheactionofGABAinthecatcentralnervoussystem. BrainRes. 1977,136,513–522. [CrossRef]
183. Volgin, A.D.; Bashirzade, A.; Amstislavskaya, T.G.; Yakovlev, O.A.; Demin, K.A.; Ho, Y.J.; Wang, D.;
Shevyrin, V.A.; Yan, D.; Tang, Z.; et al. DARK Classics in Chemical Neuroscience: Arecoline.
ACSChem.Neurosci. 2019,10,2176–2185. [CrossRef]
184. Wu,M.;Fang,M.;Hu,Y.;Wang,X.FourtypesoftraditionalChinesemedicineinducingepilepticseizures.
Seizure2012,21,311–315. [CrossRef][PubMed]
185. Shih,Y.T.;Chen,P.S.;Wu,C.H.;Tseng,Y.T.;Wu,Y.C.;Lo,Y.C.Arecoline,amajoralkaloidofthearecanut,
causesneurotoxicitythroughenhancementofoxidativestressandsuppressionoftheantioxidantprotective
system. FreeRadic. Biol. Med. 2010,49,1471–1479. [CrossRef][PubMed]
186. Mannucci,C.;Calapai,F.;Cardia,L.;Inferrera,G.;D’Arena,G.;DiPietro,M.;Navarra,M.;Gangemi,S.;
Spagnolo,E.V.;Calapai,G.Clinicalpharmacologyofcitrusaurantiumandcitrussinensisforthetreatment
ofanxiety. Evid.-BasedComplement. Altern. Med. 2018,2018,3624094. [CrossRef][PubMed]
187. Dosoky,N.S.;Setzer,W.N.Biologicalactivitiesandsafetyofcitrusspp. Essentialoils. Int. J.Mol. Sci. 2018,
19,1966. [CrossRef][PubMed]
188. Moraes, T.M.; Kushima, H.; Moleiro, F.C.; Santos, R.C.; Rocha, L.R.M.; Marques, M.O.; Vilegas, W.;
Hiruma-Lima,C.A.EffectsoflimoneneandessentialoilfromCitrusaurantiumongastricmucosa: Roleof
prostaglandinsandgastricmucussecretion. Chem. Biol. Interact. 2009,180,499–505. [CrossRef]
189. Stohs,S.J.Safety,Efficacy,andMechanisticStudiesRegardingCitrusaurantium(BitterOrange)Extractand
p-Synephrine. Phyther. Res. 2017,31,1463–1474. [CrossRef]
190. Suntar,I.;Khan,H.;Patel,S.;Celano,R.;Rastrelli,L.AnoverviewonCitrusaurantiumL.: Itsfunctionsas
foodingredientandtherapeuticagent. Oxid. Med. Cell. Longev. 2018,2018,7864269. [CrossRef]
191. Teneva,D.;Denkova-Kostova,R.;Goranov,B.;Hristova-Ivanova,Y.;Slavchev,A.;Denkova,Z.;Kostov,G.
Chemicalcomposition,antioxidantactivityandantimicrobialactivityofessentialoilfromCitrusaurantium
Lzestagainstsomepathogenicmicroorganisms. Z.Naturforsch. C.J.Biosci. 2019,74,105–111. [CrossRef]
192. Tejada,S.;Pinya,S.;Martorell,M.;Capó,X.;Tur,J.A.;Pons,A.;Sureda,A.PotentialAnti-inflammatory
EffectsofHesperidinfromtheGenusCitrus. Curr. Med. Chem. 2018,25,4929–4945. [CrossRef]
193. Wolffenbüttel, A.N.; Zamboni, A.; Becker, G.; dos Santos, M.K.; Borille, B.T.; de Cássia Mariotti, K.;
Fagundes,A.C.;deOliveiraSalomón,J.L.;Coelho,V.R.;Ruiz,L.V.;etal. Citrusessentialoilsinhalationby
mice:Behavioraltesting,GCMSplasmaanalysis,corticosterone,andmelatoninlevelsevaluation.Phyther.Res.
2018,32,160–169. [CrossRef]
194. González-Mas,M.C.;Rambla,J.L.;López-Gresa,M.P.;AmparoBlázquez,M.;Granell,A.Volatilecompounds
incitrusessentialoils: Acomprehensivereview. Front. PlantSci. 2019,10,12. [CrossRef]
195. Mahato,N.;Sharma,K.;Koteswararao,R.;Sinha,M.;Baral,E.R.;Cho,M.H.Citrusessentialoils: Extraction,
authenticationandapplicationinfoodpreservation. Crit. Rev. FoodSci. Nutr. 2019,59,611–625. [CrossRef]

## Page 47

Pharmaceuticals2020,13,309 47of51
196. Escamilla-García,M.;Calderón-Domínguez,G.;Chanona-Pérez,J.J.;Mendoza-Madrigal,A.G.;DiPierro,P.;
García-Almendárez, B.E.; Amaro-Reyes, A.; Regalado-González, C. Physical, structural, barrier,
andantifungalcharacterizationofchitosan-zeinediblefilmswithaddedessentialoils. Int. J.Mol. Sci. 2017,
18,2370. [CrossRef][PubMed]
197. Moslemi,F.;Alijaniha,F.;Naseri,M.;Kazemnejad,A.;Charkhkar,M.;Heidari,M.R.CitrusaurantiumAroma
forAnxietyinPatientswithAcuteCoronarySyndrome: ADouble-BlindPlacebo-ControlledTrial. J.Altern.
Complement. Med. 2019,25,833–839. [CrossRef][PubMed]
198. deSousa,D.P.;deAlmeidaSoaresHocayen,P.;Andrade,L.N.;Andreatini,R.Asystematicreviewofthe
anxiolytic-likeeffectsofessentialoilsinanimalmodels. Molecules2015,20,18620–18660. [CrossRef]
199. Costa,C.A.R.A.;Cury,T.C.;Cassettari,B.O.;Takahira,R.K.;Flório,J.C.;Costa,M.CitrusaurantiumL.essential
oilexhibitsanxiolytic-likeactivitymediatedby5-HT1A-receptorsandreducescholesterolafterrepeatedoral
treatment. BMCComplement. Altern. Med. 2013,13,42. [CrossRef][PubMed]
200. Akhlaghi,M.;Shabanian,G.;Rafieian-Kopaei,M.;Parvin,N.;Saadat,M.;Akhlaghi,M.CitrusAurantium
BlossomandPreoperativeAnxiety. Rev. Bras. Anestesiol. 2011,61,702–712. [CrossRef]
201. Bahr,T.A.; Rodriguez,D.; Beaumont,C.; Allred,K.Theeffectsofvariousessentialoilsonepilepsyand
acuteseizure: Asystematicreview. Evid. BasedComplement. Altern. Med. 2019,2019,6216745. [CrossRef]
[PubMed]
202. Komiya,M.;Takeuchi,T.;Harada,E.Lemonoilvaporcausesananti-stresseffectviamodulatingthe5-HT
andDAactivitiesinmice. Behav. BrainRes. 2006,172,240–249. [CrossRef]
203. Ghiasi,A.;Bagheri,L.;Haseli,A.ASystematicReviewontheAnxiolyticEffectofAromatherapyduringthe
FirstStageofLabor. J.CaringSci. 2019,8,51–60. [CrossRef][PubMed]
204. Jabri Karoui, I.; Marzouk, B. Characterization of bioactive compounds in Tunisian bitter orange
(Citrus aurantium L.) peel and juice and determination of their antioxidant activities. Biomed Res. Int.
2013,2013,345415. [CrossRef]
205. Hansen, D.K.; George, N.I.; White, G.E.; Abdel-Rahman, A.; Pellicore, L.S.; Fabricant, D.
Cardiovascular toxicity of Citrus aurantium in exercised rats. Cardiovasc. Toxicol. 2013, 13, 208–219.
[CrossRef]
206. Brown,A.C.HeartToxicityRelatedtoHerbsandDietarySupplements: OnlineTableofCaseReports. Part4
of5. J.Diet. Suppl. 2018,15,516–555. [CrossRef][PubMed]
207. Bae,K.;jiKwon,N.;Han,E.AreviewontheabuseofthreeNPS(syntheticcannabinoids,kratom,poppers)
amongyouthsinAsia. ForensicSci. Int. 2018,292,45–49. [CrossRef]
208. Singh,D.;Müller,C.P.;Vicknasingam,B.K.;Mansor,S.M.SocialFunctioningofKratom(Mitragynaspeciosa)
UsersinMalaysia. J.Psychoact. Drugs2015,47,125–131. [CrossRef]
209. Brown,P.N.;Lund,J.A.;Murch,S.J.Abotanical,phytochemicalandethnomedicinalreviewofthegenus
Mitragynakorth: Implicationsforproductssoldaskratom. J.Ethnopharmacol. 2017,202,302–325. [CrossRef]
210. Prozialeck,W.C.UpdateonthepharmacologyandlegalstatusofKratom. J.Am. Osteopath. Assoc. 2016,
116,802–809. [CrossRef]
211. Matsumoto,K.;Horie,S.;Ishikawa,H.;Takayama,H.;Aimi,N.;Ponglux,D.;Watanabe,K.Antinociceptive
effectof7-hydroxymitragynineinmice:DiscoveryofanorallyactiveopioidanalgesicfromtheThaimedicinal
herbMitragynaspeciosa. LifeSci. 2004,74,2143–2155. [CrossRef][PubMed]
212. Yamamoto,L.T.;Horie,S.;Takayama,H.;Aimi,N.;Sakai,S.I.;Yano,S.;Shan,J.;Pang,P.K.T.;Ponglux,D.;
Watanabe,K.Opioidreceptoragonisticcharacteristicsofmitragyninepseudoindoxylincomparisonwith
mitragynine derived from Thai medicinal plant Mitragyna speciosa. Gen. Pharmacol. 1999, 33, 73–81.
[CrossRef]
213. LaBryer,L.;Sharma,R.;Chaudhari,K.S.;Talsania,M.;Scofield,R.H.Kratom,anEmergingDrugofAbuse,
RaisesProlactinandCausesSecondaryHypogonadism: CaseReport. J.Investig. Med. HighImpactCaseRep.
2018,6. [CrossRef][PubMed]
214. Matsumoto,K.;Horie,S.;Takayama,H.;Ishikawa,H.;Aimi,N.;Ponglux,D.;Murayama,T.;Watanabe,K.
Antinociception,toleranceandwithdrawalsymptomsinducedby7-hydroxymitragynine,analkaloidfrom
theThaimedicinalherbMitragynaspeciosa. LifeSci. 2005,78,2–7. [CrossRef]
215. Trakulsrichai,S.;Sathirakul,K.;Auparakkitanon,S.;Krongvorakul,J.;Sueajai,J.;Noumjad,N.;Sukasem,C.;
Wananukul, W. Pharmacokinetics of mitragynine in man. Drug Des. Devel. Ther. 2015, 9, 2421–2429.
[CrossRef]

## Page 48

Pharmaceuticals2020,13,309 48of51
216. Veltri,C.;Grundmann,O.CurrentperspectivesontheimpactofKratomuse. Subst. Abus. Rehabil. 2019,
10,23–31. [CrossRef]
217. Fluyau, D.; Revadigar, N. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom.
Front.Psychiatry2017,8,62. [CrossRef][PubMed]
218. Liu, L.; Xu, F.-R.; Wang, Y.-Z. Traditional uses, chemical diversity and biological activities of Panax L.
(Araliaceae): Areview. J.Ethnopharmacol. 2020,263,112792. [CrossRef][PubMed]
219. Won,H.J.; Kim,H.,Il; Park,T.; Kim,H.; Jo,K.; Jeon,H.; Ha,S.J.; Hyun,J.M.; Jeong,A.; Kim,J.S.;etal.
Non-clinical pharmacokinetic behavior of ginsenosides. J. Ginseng Res. 2019, 43, 354–360. [CrossRef]
[PubMed]
220. Chen, W.; Balan, P.; Popovich, D.G. Chapter 6—Comparison of the ginsenoside composition of Asian
ginseng(Panaxginseng)andAmericanginseng(PanaxquinquefoliusL.)andtheirtransformationpathways.
InBioactiveNaturalProduct,1sted.;ElsevierInc.:Amsterdam,TheNetherlands,2019;Volume63,pp.161–195.
221. Leung,K.W.;Wong,A.S.Ginsengandmalereproductivefunction.Spermatogenesis2013,3,e26391.[CrossRef]
222. Mancuso,C.;Santangelo,R.PanaxginsengandPanaxquinquefolius: Frompharmacologytotoxicology.
FoodChem. Toxicol. 2017,107,362–372. [CrossRef][PubMed]
223. Ellis, J.M.; Reddy, P. Effects of Panax ginseng on quality of life. Ann. Pharmacother. 2002, 36, 375–379.
[CrossRef]
224. Lee,S.-T.;Chu,K.;Sim,J.-J.;Heo,J.-H.;Kim,M.PanaxginsengenhancescognitiveperformanceinAlzheimer
disease. AlzheimerDis. Assoc. Disord. 2008,22,222–226. [CrossRef][PubMed]
225. Heo,J.-H.;Lee,S.-T.;Oh,M.J.;Park,H.-J.;Shim,J.-Y.;Chu,K.;Kim,M.Improvementofcognitivedeficit
inAlzheimer’sdiseasepatientsbylongtermtreatmentwithKoreanredginseng. J.GinsengRes. 2011,
35,457–461. [CrossRef][PubMed]
226. Lee,N.-H.;Yoo,S.-R.;Kim,H.-G.;Cho,J.-H.;Son,C.G.Safetyandtolerabilityofpanaxginsengrootextract:
Arandomized,placebo-controlled,clinicaltrialinhealthyKoreanvolunteers. J.Altern. Complement. Med.
2012,18,1061–1069. [CrossRef][PubMed]
227. Steiner,G.Z.;Yeung,A.;Liu,J.X.;Camfield,D.A.;deBlasio,F.M.;Pipingas,A.;Scholey,A.B.;Stough,C.;
Chang,D.H.TheeffectofSailuotong(SLT)onneurocognitiveandcardiovascularfunctioninhealthyadults:
Arandomised,doubleblind,placebocontrolledcrossoverpilottrial. BMCComplement. Altern. Med. 2016,
16,15. [CrossRef]
228. Keshavan, M.; Jones, D.A.; Dube, S.; Grabowski, J.; Bell, J.; Sitaram, N. Cardioacceleratory responses
to arecoline infusion during sleep in depressive, anxious, and normal subjects. Biol. Psychiatry 1987,
22,1473–1477. [CrossRef]
229. Coon,J.T.;Ernst,E.Panaxginseng: Asystematicreviewofadverseeffectsanddruginteractions. DrugSaf.
2002,25,323–344. [CrossRef]
230. Woron´,J.;Siwek,M.Unwantedeffectsofpsychotropicdruginteractionswithmedicinalproductsanddiet
supplementscontainingplantextracts. Psychiatr. Pol. 2018,52,983–996. [CrossRef][PubMed]
231. Choi,M.K.;Song,I.S.Interactionsofginsengwiththerapeuticdrugs. Arch. Pharm. Res. 2019,42,862–878.
[CrossRef]
232. Liu,Y.;Yu,H.Y.;Xu,H.Z.;Liu,J.J.;Meng,X.G.;Zhou,M.;Ruan,H.L.AlkaloidswithImmunosuppressive
ActivityfromtheBarkofPausinystaliayohimbe. J.Nat. Prod. 2018,81,1841–1849. [CrossRef]
233. Sun,J.;Baker,A.;Chen,P.Profilingtheindolealkaloidsinyohimbebarkwithultra-performanceliquid
chromatographycoupledwithionmobilityquadrupoletime-of-flightmassspectrometry. RapidCommun.
MassSpectrom. 2011,25,2591–2602. [CrossRef]
234. Raman,V.;Avula,B.;Galal,A.M.;Wang,Y.H.;Khan,I.A.MicroscopicandUPLC-UV-MSanalysesofauthentic
andcommercialyohimbe(Pausinystaliajohimbe)barksamples. J.Nat. Med. 2013,67,42–50. [CrossRef]
[PubMed]
235. Cohen,P.A.;Wang,Y.H.;Maller,G.;Desouza,R.;Khan,I.A.Pharmaceuticalquantitiesofyohimbinefound
indietarysupplementsintheUSA.DrugTest. Anal. 2016,8,357–369. [CrossRef]
236. Uhde,T.W.;Boulenger,J.P.;Post,R.M.;Siever,L.J.;Vittone,B.J.;Jimerson,D.C.;Roy-Byrne,P.P.Fearand
anxiety: Relationship to noradrenergic function. Psychopathology 1984, 17 (Suppl. 3), 8–23. [CrossRef]
[PubMed]

## Page 49

Pharmaceuticals2020,13,309 49of51
237. Cai,L.;Bakalli,H.;Rinaman,L.Yohimbineanxiogenesisintheelevatedplusmazeisdisruptedbybilaterally
disconnectingthebednucleusofthestriaterminalisfromthecentralnucleusoftheamygdala. Neuroscience
2012,223,200–208. [CrossRef][PubMed]
238. Tam,S.W.;Worcel,M.;Wyllie,M.Yohimbine:Aclinicalreview. Pharmacol. Ther. 2001,91,215–243. [CrossRef]
239. Owen,J.A.;Nakatsu,S.L.;Fenemore,J.;Condra,M.;Surridge,D.H.C.;Morales,A.Thepharmacokineticsof
yohimbineinman. Eur. J.Clin. Pharmacol. 1987,32,577–582. [CrossRef][PubMed]
240. Berlan,M.;LeVerge,R.;Galitzky,J.;LeCorre,P.α2-Adrenoceptorantagonistpotenciesoftwohydroxylated
metabolitesofyohimbine. Br. J.Pharmacol. 1993,108,927–932. [CrossRef]
241. Kearney, T.; Tu, N.; Haller, C. Adverse drug events associated with yohimbine-containing products:
AretrospectivereviewoftheCaliforniapoisoncontrolsystemreportedcases. Ann. Pharmacother. 2010,
44,1022–1029. [CrossRef]
242. Shannon,M.;Neuman,M.I.Yohimbine. Pediatr. Emerg. Care2000,16,49–50. [CrossRef][PubMed]
243. Rothschild,A.J.Newdirectionsinthetreatmentofantidepressant-inducedsexualdysfunction. Clin. Ther.
2000,22,A42–A57. [CrossRef]
244. Shamloul,R.Naturalaphrodisiacs. J.Sex. Med. 2010,7,39–49. [CrossRef][PubMed]
245. West,E.;Krychman,M.NaturalAphrodisiacs-AReviewofSelectedSexualEnhancers. Sex. Med. Rev. 2015,
3,279–288. [CrossRef][PubMed]
246. Cimolai,N.;Cimolai,T.Yohimbineuseforphysicalenhancementanditspotentialtoxicity. J.Diet. Suppl.
2011,8,346–354. [CrossRef]
247. Yang, H.L.; Yang, T.Y.; Gowrisankar, Y.V.; Liao, C.H.; Liao, J.W.; Huang, P.J.; Hseu, Y.C. Suppression
of LPS-Induced Inflammation by Chalcone Flavokawain A through Activation of Nrf2/ARE-Mediated
AntioxidantGenesandInhibitionofROS/NFκBSignalingPathwaysinPrimarySplenocytes. Oxid. Med.
Cell. Longev. 2020,2020,3476212. [CrossRef][PubMed]
248. Baker,J.D.Pills,potions,products: Kava’stransformationsinnewandnontraditionalcontexts. Contemp.Pac.
2012,24,233–265. [CrossRef]
249. Xuan,T.D.;Fukuta,M.;Wei,A.C.;Elzaawely,A.A.;Khanh,T.D.;Tawata,S.Efficacyofextractingsolvents
tochemicalcomponentsofkava(Pipermethysticum)roots. J.Nat. Med. 2008,62,188–194. [CrossRef]
[PubMed]
250. Teschke,R.;Qiu,S.X.;Lebot,V.Herbalhepatotoxicitybykava: Updateonpipermethystine,flavokavainB,
andmouldhepatotoxinsasprimarilyassumedculprits. Dig. LiverDis. 2011,43,676–681. [CrossRef]
251. Baum,S.S.;Hill,R.;Rommelspacher,H.Effectofkavaextractandindividualkavapyronesonneurotransmitter
levelsinthenucleusaccumbensofrats. Prog. Neuropsychopharmacol. Biol. Psychiatry1998,22,1105–1120.
[CrossRef]
252. Boonen,G.;Ferger,B.;Kuschinsky,K.;Häberlein,H.Invivoeffectsofthekavapyrones(+)-dihydromethysticin
and(±)-kavainondopamine,3,4-dihydroxyphenylaceticacid,serotoninand5-hydroxyindoleaceticacid
levelsinstriatalandcorticalbrainregions. PlantaMed. 1998,64,507–510. [CrossRef][PubMed]
253. Anke,J.;Ramzan,I.PharmacokineticandpharmacodynamicdruginteractionswithKava(Pipermethysticum
Forst. f.). J.Ethnopharmacol. 2004,93,153–160. [CrossRef][PubMed]
254. Mathews, J.M.; Etheridge, A.; Valentine, J.L.; Black, S.R.; Coleman, D.P.; Patel, P.; So, J.; Burka, L.T.
Pharmacokineticsanddispositionofthekavalactonekawain: Interactionwithkavaextractandkavalactones
invivoandinvitro. DrugMetab. Dispos. 2005,33,1555–1563. [CrossRef]
255. Fu,P.P.;Xia,Q.;Guo,L.;Yu,H.;Chan,P.C.Toxicityofkavakava. J.Environ. Sci. HealthCEnviron. Carcinog.
Ecotoxicol. Rev. 2008,26,89–112. [CrossRef][PubMed]
256. Clough,A.R.;Bailie,R.S.;Currie,B.LiverFunctionTestAbnormalitiesinUsersofAqueousKavaExtracts.
J.Toxicol. Clin. Toxicol. 2003,41,821–829. [CrossRef]
257. White,C.M.ThePharmacology,Pharmacokinetics,Efficacy,andAdverseEventsAssociatedWithKava.
J.Clin.Pharmacol. 2018,58,1396–1405. [CrossRef][PubMed]
258. deVargas,F.S.; Almeida,P.D.O.; deBoleti,A.P.A.; Pereira,M.M.; deSouza,T.P.; deVasconcellos,M.C.;
Nunez,C.V.;Pohlit,A.M.;Lima,E.S.AntioxidantactivityandperoxidaseinhibitionofAmazonianplants
extractstraditionallyusedasanti-inflammatory. BMCComplement. Altern. Med. 2016,16,83. [CrossRef]
[PubMed]

## Page 50

Pharmaceuticals2020,13,309 50of51
259. Siqueira, I.R.; Fochesatto, C.; Da Silva, A.L.; Nunes, D.S.; Battastini, A.M.; Netto, C.A.; Elisabetsky, E.
Ptychopetalum olacoides, a traditional Amazonian “nerve tonic”, possesses anticholinesterase activity.
Pharmacol. Biochem. Behav. 2003,75,645–650. [CrossRef]
260. Siqueira,I.R.;Lara,D.R.;Silva,D.;Gaieski,F.S.;Nunes,D.S.;Elisabetsky,E.Psychopharmacologicalproperties
ofPtycopetalumolacoidesBentham(Olacaceae). Pharm. Biol. 1998,36,327–334. [CrossRef]
261. Pankow, E.; Auterhoff, H. Contents of Muira puama. 2. Arch. Pharm. Ber. Dtsch. Pharm. Ges. 1969,
302,209–212. [CrossRef]
262. Novello, C.R.; Marques, L.C.; Miyazaki, C.R.; Milaneze-Gutierre, M.A.; Carneiro-Torres, D.S.;
Sarragiotto,M.H.; deMello,J.C.P.MorphoanatomyandpharmacognosticstudyofthewoodofCroton
echioides,theNortheasternMarapuama. Braz. J.Pharmacogn. 2012,22,946–956. [CrossRef]
263. Vaz,Z.R.;Mata,L.V.;Calixto,J.B.AnalgesiceffectoftheherbalmedicineCatuamainthermalandchemical
modelsofnociceptioninmice. Phyther. Res. 1997,11,101–106. [CrossRef]
264. Muszyn´ska,B.;Łojewski,M.;Rojowski,J.;Opoka,W.;Sułkowska-Ziaja,K.Naturalproductsofrelevance
inthepreventionandsupportivetreatmentofdepression. Psychiatr. Pol. 2015,49,435–453. [CrossRef]
[PubMed]
265. Dimpfel,W.;Franklin,R.;Gericke,N.;Schombert,L.EffectofZembrin ® andfourofitsalkaloidconstituents
onelectricexcitabilityoftherathippocampus. J.Ethnopharmacol. 2018,223,135–141. [CrossRef][PubMed]
266. Manda, V.K.; Avula, B.; Ashfaq, M.K.; Abe, N.; Khan, I.A.; Khan, S.I. Quantification of mesembrine
andmesembrenoneinmouseplasmausingUHPLC-QToF-MS:Applicationtoapharmacokineticstudy.
Biomed.Chromatogr. 2017,31,e3815. [CrossRef]
267. Zhao,J.;Khan,I.A.;Combrinck,S.;Sandasi,M.;Chen,W.;Viljoen,A.M.1H-NMRandUPLC-MSmetabolomics:
FunctionaltoolsforexploringchemotypicvariationinSceletiumtortuosumfromtwoprovincesinSouth
Africa. Phytochemistry2018,152,191–203. [CrossRef]
268. Smith,M.T.;Crouch,N.R.;Gericke,N.;Hirst,M.PsychoactiveconstituentsofthegenusSceletiumN.E.Br.
andotherMesembryanthemaceae: Areview. J.Ethnopharmacol. 1996,50,119–130. [CrossRef]
269. Cashman,J.R.;Voelker,T.;Johnson,R.;Janowsky,A.Stereoselectiveinhibitionofserotoninre-uptakeand
phosphodiesterasebydualinhibitorsaspotentialagentsfordepression. Bioorg. Med. Chem. 2009,17,337–343.
[CrossRef]
270. Loria,M.J.;Ali,Z.;Abe,N.;Sufka,K.J.;Khan,I.A.EffectsofSceletiumtortuosuminrats. J.Ethnopharmacol.
2014,155,731–735. [CrossRef]
271. Harvey, A.L.; Young, L.C.; Viljoen, A.M.; Gericke, N.P. Pharmacological actions of the South African
medicinalandfunctionalfoodplantSceletiumtortuosumanditsprincipalalkaloids. J.Ethnopharmacol. 2011,
137,1124–1129. [CrossRef]
272. Smith,C.TheeffectsofSceletiumtortuosuminaninvivomodelofpsychologicalstress. J.Ethnopharmacol.
2011,133,31–36. [CrossRef][PubMed]
273. Carpenter, J.M.; Jourdan, M.K.; Fountain, E.M.; Ali, Z.; Abe, N.; Khan, I.A.; Sufka, K.J. The effects of
Sceletiumtortuosum(L.)N.E.Br. extractfractioninthechickanxiety-depressionmodel. J.Ethnopharmacol.
2016,193,329–332. [CrossRef][PubMed]
274. Stafford,G.I.;Pedersen,M.E.;vanStaden,J.;Jäger,A.K.ReviewonplantswithCNS-effectsusedintraditional
SouthAfricanmedicineagainstmentaldiseases. J.Ethnopharmacol. 2008,119,513–537. [CrossRef]
275. Terburg, D.; Syal, S.; Rosenberger, L.A.; Heany, S.; Phillips, N.; Gericke, N.; Stein, D.J.; Van Honk, J.
Acuteeffectsofsceletiumtortuosum(Zembrin),adual5-HTreuptakeandPDE4inhibitor,inthehuman
amygdalaanditsconnectiontothehypothalamus. Neuropsychopharmacology2013,38,2708–2716. [CrossRef]
276. Coetzee,D.D.;López,V.;Smith,C.High-mesembrineSceletiumextract(TrimesemineTM)isamonoamine
releasingagent,ratherthanonlyaselectiveserotoninreuptakeinhibitor.J.Ethnopharmacol.2016,177,111–116.
[CrossRef][PubMed]
277. Bennett,A.C.;Smith,C.ImmunomodulatoryeffectsofSceletiumtortuosum(TrimesemineTM)elucidated
invitro: Implicationsforchronicdisease. J.Ethnopharmacol. 2018,214,134–140. [CrossRef]
278. Krstenansky, J.L. Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology.
J.Ethnopharmacol. 2017,195,10–19. [CrossRef]
279. Beharry,S.;Heinrich,M.Isthehypearoundthereproductivehealthclaimsofmaca(Lepidiummeyenii
Walp.) justified? J.Ethnopharmacol. 2018,211,126–170. [CrossRef]
280. Quandt,P.;Puga,M.Manicepisodesecondarytomaca. Eur. Psychiatry2016,33,S339. [CrossRef]

## Page 51

15fo15
903,31,0202slacituecamrahP
erachtlaehstignithgilhgihahdnagawhsAfonoitaulavelacigolocamrahP.G.A,oedmaN;.M.S.D,elawagnI
.182
]feRssorC[
.44–1,0202
.lppuS
.teiD.J
.stcepsayticixotdna,ytefas,smialc
namuhnitoorlanuD
).nniL(arefinmoSainahtiWfossenevitceffelacinilcdnaytefaS.S.S,vadaY;.N,nodnaT
.282
]deMbuP[]feRssorC[
.867211,552,0202
.locamrahponhtE.J
.stnemlia
)eaecarenruT(dliWasuffidarenruTfostceffelauxes-orP.L,atoM-zenítraM;.M,zeráuJ-orraC;.R,seyeR-adartsE
.382
]deMbuP[]feRssorC[
.271–461,641,3102
.locamrahponhtE.J
.yawhtapedixocirtinehtsevlovnistarelamni
dnalaroivaheborueN.R.E,asoR
;.P-.G,racsO
;.M-.M,aícuL
;.N-.M,nailiL
;.R.V.V,aíraM
;.A.B-.D,aíraM
.482
.locamrahponhtE.J
.ecimni)eaecarenruT(dlliWasuffidarenruTfotcartxesuoeuqanafostceffelacigolocixot
]deMbuP[]feRssorC[
.26–05,632,9102
.latroPyteicoS&tnemnorivnE|ciledehcysPlainomereCasaanacirfaagnacaoVfonoitnevnIehT.T,etaigliV
.582
-lainomerec-anacirfa-agnacaov-noitnevni/aidacra/gro.yteicosdnatnemnorivne.www//:ptth
:enilnoelbaliavA
.)0202tsuguA72nodessecca(ciledehcysp
.42–9,511,8002
.locamrahponhtE.J
.erutlucbuslacidemeniagobiehT.D.C,nalpaK;.S.H,fostoL;.R.K,replA
.682
]feRssorC[
dnaeniagobI.J.Q,namttiP;.K.J,iniwmalouB;.J.J,utubakA;.X,nehC;.Y.I.N,ebgaiF;.M.T,helaS;.B.S,naibmoK
.782
ninoissimsnartcitpanysdnaytilibaticxelanoruenetaludomanacirfaagnacaoVfotcartxeladiolaklalatota
]feRssorC[
.016–306,44,7991
.lluB
.seRniarB
.ortivnisuelcunlaihcarbaraptareht
;.M,arierudaMuéCoD;.J,aviaP;.T.M,atsitaB;.T,sotnaS;.G,atsoC;.M,cizrvS-nojuoG;.C,aturihC;.A,siarruC
.882
morfesaesids’remiehzlAottnavelersdnuopmocevitcetorporuenfonoitacfiitnedidnagnineercS.P,rehaM
]feRssorC[
.048–038,551,4102
.locamrahponhtE.J
.epicnírPeémoT.Sfostnalplanicidem
.stcudorplarutanmorfenicidemnredomdnaenicidemlanoitidartehT.G,oaiP;.L,eY;.Q,aM;.H,nauY
.982
]feRssorC[
.955,12,6102seluceloM
]feRssorC[
.748,933,8991
.deM.J
.lgnE.N
.senicidemtnetapnaisAnistnaretludA.J.R,oK
.092
:enilno
elbaliavA
.3202–4102
ygetartS
enicideM
lanoitidarT
OHW
.)OHW(
noitazinagrO
htlaeH
dlroW
.192
=dinoissesj;fdp.gne_0906051429879/55429/56601/eldnah/maertstib/siri/tni.ohw.sppa//:sptth
.)0202tsuguA72nodessecca(1=ecneuqes?386AB3417601035FA7685F98E8B79A55
lanoitutitsnidnaspamdehsilbupnismialclanoitcidsirujotdragerhtiwlartuensyatsIPDM
:etoNs’rehsilbuP
.snoitailffia
sseccaneponasielcitrasihT
.dnalreztiwS,lesaB,IPDMeesneciL
.srohtuaehtyb0202©
noitubirttAsnommoCevitaerCehtfosnoitidnocdnasmretehtrednudetubirtsidelcitra
.)/0.4/yb/sesnecil/gro.snommocevitaerc//:ptth(esnecil)YBCC(
9 ...

